

- 1 -

**CLONING AND CHARACTERISATION OF  
NOVEL MAMMALIAN PEPTIDASES**

The present invention is concerned with novel  
5 mammalian peptidases and, in particular, with  
peptidases designated NAALAD-ase (N-acetylated alpha-  
linked acidic dipeptidases), cDNA sequences encoding  
for said peptidases and methods of identifying  
compounds which inhibit or enhance the activity or  
10 expression of such peptidases in addition to the  
compounds so identified.

NAALAD-ase I has previously been identified as a  
type II membrane glycoprotein with carboxypeptidase  
activity and sequence similarity to the transferrin  
15 receptor and which may be important in the progression  
of prostate cancer, being highly expressed in prostate  
tumours. In the CNS it has been postulated to have a  
role in modulating neuronal glutameric activity. The  
nucleotide and amino acid sequences for NAALAD-ase I  
20 have previously been identified (US 5,538,686).

The present inventors have now surprisingly  
identified and cloned cDNA molecules which represent  
an expansion of this family of proteins and which  
enzymes have never previously been identified or  
25 characterised.

Therefore, according to a first aspect of the  
present invention, there is provided a cDNA molecule  
encoding a peptidase designated human NAALAD-ase L  
30 having the amino acid sequence illustrated in Figure 1  
or a functional equivalent or derivative or  
bioprecursor thereof. Preferably, the cDNA molecule  
comprises the sequence of nucleotides illustrated in  
Figure 1. Also provided by the present invention are  
splice variants of the human NAALAD-ase L protein  
35 illustrated in Figure 3 and preferably which splice  
variants are encoded by the nucleotide deletions or

- - 2 -

insertions indicated in Figure 3.

According to a further aspect of the present invention there is provided a cDNA molecule encoding a peptidase designated NAALAD-ase II or IV having the 5 amino acid sequences as illustrated in Figures 4 and 5 respectively. Preferably, the cDNA comprises the sequences of nucleotides illustrated in Figures 4 and 5 respectively. Also encompassed within the present invention are nucleic acid molecules capable of 10 hybridising to the cDNA molecules according to the invention.

Also provided by the present invention are the NAALAD-ase proteins encoded by the DNA sequences according to the invention. Therefore, according to a 15 further aspect of the invention there is provided a human NAALAD-ase L protein having an amino acid sequence encoded by the nucleotide sequence illustrated in Figure 1 or the sequence of Figure 1 including the insertions or deletions illustrated in 20 Figure 3. Preferably, the NAALAD-ase L protein comprises a human NAALAD-ase L protein. Also provided by the present invention is a NAALAD-ase II and IV protein having amino acid sequences encoded by the nucleotide sequences illustrated in Figure 4 and 5 25 respectively or a functional equivalent, derivative or bioprecursor thereof and which protein is preferably of human origin. Preferably, the NAALAD-ase II and IV proteins comprise the amino acid sequences illustrated in Figures 4 and 5 respectively.

There is also provided by the invention an 30 antisense molecule capable of hybridising to any of the nucleic acid sequences according to the invention, under high stringency conditions, which would be well known to those skilled in the art.

Stringency of hybridisation as used herein refers 35 to conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the

- 3 -

melting temperature ( $T_m$ ) of the hybrids.  $T_m$  can be approximated by the formula:

$$81.5^{\circ}\text{C}-16.6 \ (\log_{10}[\text{Na}^+]+0.41 \ (\%G\&C)-600/l$$

5

wherein l is the length of the hybrids in nucleotides.  $T_m$  decreases approximately by 1-1.5°C with every 1% decrease in sequence homology.

The cDNA molecules according to the invention  
10 may advantageously be included in an expression vector which may itself be used to transform, transfect or infect a host cell, which cell may be bacterial or eukaryotic in origin. Thus, advantageously, a range of cells, tissues or organisms may be transfected  
15 following incorporation of the appropriate cDNA into the expression vector. The vector may include an appropriate promoter, such as a cytomegalovirus promoter and optionally a sequence encoding a reporter molecule such as, for example, green fluorescent  
20 protein.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector  
25 may include a promoter such as the lac promoter and for transcription initiations the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase  
30 II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art.

35 Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that upon

- - 4 -

introduction into an appropriate host cell results in expression of the DNA or RNA fragments. Appropriate expression vectors are well known to those skilled in the art and include those that are replicable in 5 eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

10 The antisense molecule capable of hybridising to the nucleic acid according to the invention may be used as a probe or as a medicament or in a pharmaceutical composition.

15 Nucleic acid molecules according to the invention may be inserted into the vectors described in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

20 A further aspect of the invention comprises the host cell transformed, transfected or infected with the expression vector according to the invention, which cell preferably comprises a eukaryotic cell and more preferably a mammalian cell.

25 Incorporation of cloned DNA into a suitable expression vector for subsequent transformation of said cell and subsequent selection of the transformed cells is well known to those skilled in the art as provided in Sambrook et al (1989) Molecular Cloning, A Laboratory manual, Cold Spring Harbour Laboratory Press.

30 The present invention also comprises a transgenic cell, tissue or organism comprising a transgene, capable of expressing a NAALAD-ase protein according to the invention.

35 The term "transgene capable" of expression the protein according to the invention, as used herein should be taken to mean a suitable nucleic acid sequence which leads to the expression of said protein

- - 5 -

according to the invention or a protein having the same function or activity. The transgene may include, for example, genomic nucleic acid isolated from a human source or synthetic nucleic acid, inducing cDNA.

5      The term "transgenic organism, tissue or cell" as used herein means any suitable organism and/or part of an organism, tissue or cell, that contains exogenous nucleic acid either stably integrated in the genome or in an extrachromosomal state. The transgenic cell is

10     preferably a COS cell. Preferably, the transgene comprises an expression vector according to the invention.

The term "functional fragment" as used herein should be taken to mean a fragment of the gene encoding the NAALAD-ase protein according to the invention. For example, the gene may comprise deletions or mutations but may still encode a functional NAALAD-ase protein.

In accordance with the present invention, a defined nucleic acid sequence includes not only the identical nucleic acid but also minor base variations from the natural nucleic acid sequence, including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid) due to the degenerate code in conservative amino acid substitution. The term "nucleic acid or cDNA sequence" also includes the complementary sequence to any single stranded sequence given which includes the definition given above regarding base variations.

Furthermore, a defined protein, polypeptide or amino acid sequence according to the invention includes not only the identical amino acid sequence but also minor amino acid variations from the natural amino acid sequence including conservative amino acid replacements (a replacement by an amino acid that is related in its side chains). Also included are amino

-- 6 --

acid sequences which vary from the natural amino acid but result in a polypeptide which is immunologically identical or similar to the polypeptide encoded by the naturally occurring sequence.

5 A further aspect of the invention provides a nucleic acid sequence of at least 15 nucleotides of a nucleic acid according to the invention and preferably from 15 to 50 nucleotides.

10 These sequences may, advantageously be used as probes or primers to initiate replication or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting for the 15 presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with a sample under hybridising conditions and detecting for the presence of any duplex formation between the probe and any nucleic acid in the sample.

20 Nucleic acid sequences according to the invention may also be produced using recombinant or synthetic means such as described in Sambrook et al (Molecular Cloning: A Laboratory Manual, 1989). Advantageously, human allelic variants or polymorphisms of the DNA 25 according to the invention may be identified by, for example, probing DNA libraries from a range of individuals for example from different populations. Furthermore, nucleic acids and probes according to the invention may be used to sequence genomic DNA from 30 patients using techniques well known in the art, such as the Sanger Dideoxy chain termination method, which may advantageously ascertain any predisposition of a patient to certain proliferative disorders.

35 The nucleic acids or oligonucleotides according to the invention may carry a revealing label. Suitable labels include radioisotopes such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , enzyme labels or other protein labels such as biotin or

- 7 -

fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques *per se*.

Advantageously, human allelic variants or 5 polymorphisms of the DNA molecule according to the invention may be identified by, for example, probing cDNA or genomic libraries from a range of individuals for example from different populations. Furthermore, 10 nucleic acids and probes according to the invention may be used to sequence genomic DNA from patients using techniques well known in the art, such as the Sanger Dideoxy chain termination method, which may advantageously ascertain any predisposition of a patient to certain disorders associated with a 15 NAALAD-ase according to the invention.

A nucleic acid sequence or protein identified according to the present invention may advantageously be used as a medicament, or in the preparation of a medicament for treating cancer or neurodegenerative 20 disorders such as Alzheimer's disease or ALS, and other diseases or disorders mediated by peptidases according to the present invention. Advantageously, the cDNA and protein according to the invention in addition to nucleic acids hybridisable to the cDNA may 25 also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor. Thus, the composition may comprise antisense nucleic acids for use in, for example, gene therapy.

The present invention is further directed to 30 inhibiting a NAALAD-ase according to the invention *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or 35 RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the part of the DNA sequence coding for the mature protein of

-- 8 --

the present invention is used to design an antisense RNA oligonucleotide of from 10 to 50 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in  
5 transcription (triple-helix - see Lee et al. Nucl. Acids. Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991), thereby preventing transcription and the production of the peptidase. The antisense RNA  
10 oligonucleotide hybridises to the mRNA *in vivo* and blocks translation of an mRNA molecule into the NAALAD-ase.

Further provided by the present invention is a method of determining whether a compound is an inhibitor or an enhancer of NAALAD-ase activity, which method comprises contacting said compound in the presence of [<sup>3</sup>H]N-acetyl-L-aspartyl-L-glutamate (NAAG), and monitoring for the extent of hydrolysis of said NAAG.

NAALAD-ase peptides have previously been reported to have a role in prostate and other potential cancers in which case compounds identified as either inhibitors or enhancers of NAALAD-ase activity may advantageously be used as medicaments, or in the preparation of medicaments for treating cancers or neurodegenerative diseases such as Alzheimer's disease or ALS. These compounds may also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

A further aspect of the present invention comprises a method of identifying a compound which is an inhibitor or an enhancer of expression of a NAALAD-ase protein according to the invention which method comprises contacting a host cell, tissue or organism expressing said protein with said compound and monitoring the expression of said protein compared to

- 9 -

a control which comprises a cell expressing said peptidase according to the invention but which has not been contacted with said compound.

Preferably, said NAALAD-ase expressing cell  
5 comprises a host cell according to the invention or a transgenic cell, tissue or organism as described above. Preferably, said monitoring step comprises monitoring for the expression of said reporter molecule.

10 Compounds identified according to the above identified method may also be used as a medicament or in the preparation of a medicament for treating neurodegenerative disorders such as Alzheimer's disease, schizophrenia or ALS. Such compounds may  
15 also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor to the present invention may also be prepared.

20 The NAALAD-ase antisense molecules or indeed the compounds identified as agonists or antagonists of the NAALAD-ase according to the invention may be used in the form of a pharmaceutical composition, which may be prepared according to procedures well known in the art. Preferred compositions include a  
25 pharmaceutically acceptable vehicle or diluent or excipient, such as for example, a physiological saline solution. Other pharmaceutically acceptable carriers including other non-toxic salts, sterile water or the like may also be used. A suitable buffer may also be  
30 present allowing the compositions to be lyophilized and stored in sterile conditions prior to reconstitution by the addition of sterile water for subsequent administration. Incorporation of  
NAALAD-ase into a solid or semi-solid biologically  
35 compatible matrix may be carried out which can be implanted into tissues requiring treatment.

Antibodies to the NAALAD-ase peptidases according

-- 10 --

to the present invention may, advantageously be prepared according to those techniques known in the art. Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected 5 peptides. Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Alternatively, monoclonal 10 antibodies may be produced in *in vitro* techniques known to persons of ordinary skill in the art.

The antibodies prepared may be used in a method for detecting for the presence of said NAALAD-ase peptidases according to the invention by reacting said 15 antibodies with a sample to be tested and identifying any protein bound thereto. A kit for such a method may also be provided and which comprises an antibody according to the aspect of the invention described above and means for reacting said antibody with said 20 sample.

The carrier can also contain other pharmaceutically acceptable excipients for modifying other conditions such as pH, osmolarity, viscosity, sterility, lipophilicity, solubility or the like. 25 Pharmaceutically acceptable excipients which permit sustained or delayed release following administration may also be included.

The NAALAD-ase protein or the nucleic acid molecules or compounds according to the invention may 30 be administered orally. In this embodiment they may be encapsulated and combined with suitable carriers in solid dosage forms which would be well known to those skilled in the art.

As would be well known to those of skill in the 35 art, the specific dosage regime may be calculated according to the body surface area of the patient or the volume of body space to be occupied, dependent

- - 11 -

upon the particular route of administration to be used. The amount of the composition actually administered will, however, be determined by a medical practitioner, based on the circumstances pertaining to  
5 the disorder to be treated, such as the severity of the symptoms, the composition to be administered, the age, weight, and response of the individual patient and the chosen route of administration.

10 A functionally active dose of such compounds according to the present invention comprises 300 ng/kg to 300 $\mu$ g/kg in a rat. As aforementioned a skilled practitioner would arrive at an appropriate dosage for human subjects based on the relevant factors discussed.

15 The present invention may be more clearly understood by the following examples, which are purely exemplary, with reference to the accompanying drawings wherein:

20 Figure 1: is an illustration of the nucleotide and amino acid sequences of human NAALAD-ase L. The nucleotide and predicted single letter code amino acid sequence are shown. The putative membrane spanning domain, deduced from hydrophilicity plots, is marked  
25 by a line. Potential N-glycosylation sites are shaded.

Figure 2: is an alignment of the predicted protein sequences for human and rat NAALAD-ase L. The amino acid sequences were aligned using the ClustalW  
30 alignment program (EMBL, Heidelberg Germany). Amino acid residues identical in both proteins are highlighted in black. Amino acid residues are numbered in the right hand margin.

35

Figure 3: is an illustration of alternative splicing of NAALAD-ase L. Amino acid sequence for NAALAD-ase L

- - 12 -

is shown. Sites at which putative DNA sequences are spliced out are marked by an arrow with the resulting (in-frame) amino acid deletions highlighted in bold italicised letters. Sites of putative intronic DNA 5 insertion are marked by triangles, with the intronic DNA sequence shown above. Resulting changes to the amino acid sequence are highlighted in bold italicised letters. Numbering of amino acid residues is to the right.

10

Figure 4: is a nucleotide and amino acid sequence of human NAALAD-ase II. The nucleotide and predicted one letter code amino acid sequence are shown. The putative membrane spanning domain, deduced from 15 hydrophilicity plots, is marked by a line. Potential N-glycosylation sites are shaded.

Figure 5: is a nucleotide sequence and amino acid sequence of human NAALAD-ase IV. The nucleotide and predicted one letter code amino acid sequence are shown. The putative membrane spanning domain, deduced from hydrophilicity plots, is marked by a line. 20 Potential N-glycosylation sites are shaded.

25 Figure 6: is an alignment of the predicted protein sequences for human NAALAD-ases I, L, II & IV. The amino acid sequences were aligned using the ClustalW alignment program. Amino acid residues identical to all four proteins are shaded in black. Amino acid 30 residues identical to three of the four proteins are shaded in grey. Amino acid residues are numbered to the right. A putative Zn<sup>2+</sup> peptidase domain is highlighted between arrows and was identified by comparison to yeast and bacterial aminopeptidases. 35 Putative residues involved in the catalytic site of the α/β hydrolase fold family of proteins are marked by three arrows (nucleophile-acid-base).

- 13 -

Figure 7: is a phylogram of NAALAD-ase I, L, II and IV. The human and rat sequences were used and the alignments performed with the CLUSTALW program. The tree was constructed using the GCG 'Distances' program with standard parameters and the 'Growtree' program with the UPGMA method.

Figure 8: is an alignment of the NAALAD-ase peptidase domains with related peptidases. Amino acid sequences were aligned using the standard settings of CLUSTALW alignment program. Similar amino acid residues conserved in proteins are shaded in black. Similar amino acid residues conserved in 80% of the proteins are shaded in dark grey. Similar amino acid residues conserved in 60-79% of the proteins are shaded in light grey. Amino acid residues are numbered to the right. Putative residues involved in zinc binding are marked by asterisks. The base residue thought to be important in catalysis is marked by an arrow.

Sequence names other than NAALAD-ases correspond to sequence accession numbers in Swiss-Prot and SPTREMBL; Ape 3 yeast, *Saccharomyces cervisiae* aminopeptidase Y; P96152, *Vibrio cholerae* aminopeptidase; .Ampx vibpr, *Aeromonas proteolyticus* aminopeptidase, Application strgr, *Streptomyces griseus* aminopeptidase. Putative residues involved in zinc binding are marked by asterisks. General base residue thought to be important in catalysis is marked by an arrow.

Figure 9: is an illustration of time course of NAALAD-ase activity. Activity of membrane preparations from COS cells transiently transfected with either NAALAD-ase I (A) or NAALAD-ase L (B). Hydrolysis of 500 nM  $^3\text{H}$ -NAAG in 1mM ZnCl<sub>2</sub>, 50 mM Tris.HCL (pH 7.4) was assayed for 0, 15, 30 and 60 min at 37°C in the presence (open circles) or absence (closed circles) of 30  $\mu\text{M}$  quisqualate. Reactions were terminated with 250

- - 14 -

mM ice cold sodium phosphate and released 3[H]-glutamate measured. (C) Inhibition of NAALAD-ase I (open circles) and NAALAD-ase II (closed circles) activity by increasing concentrations of quisqualic acid expressed as % of control (activity in the absence of any inhibitor).

Figure 10: is an illustration of NAALAD-ase activity determinations using SPA beads. (A) 10 µg of protein from LNCaP cell membrane preparations was used per reaction to develop a high throughput assay NAALAD-ase assay. Hydrolysis of 40 nM 3[H]-NAAG in 1mM ZnCl<sub>2</sub>, 50 mM Tris-HCL (pH 7.4) was measured at 25°C for different incubation times in a 100 µl reaction volume. Reactions were terminated by the addition of 100 µl glycine buffer (pH 3.0) and naked YS-SPA beads. (C) Inhibition of NAALAD-ase I (open circles) or LNCaP membrane NAALAD-ase (closed circles) activity by increasing concentrations of quisqualic acid expressed as a % of control (activity in the absence of any inhibitor).

Figure 11: is an illustration of chromosomal localisation of human NAALAD-ases. Diagrams of FISH mapping results for NAALAD-ase I (A), L (C) II (E) and IV (G). In each diagram dots represent the double FISH signals detected on identified chromosomes. Examples of FISH mapping of NAALAD-ase I (B), L (D), II (F) and IV (:H). Left panels show the FISH signals on the identified chromosome marked by a white arrow, right panels show the same mitotic Figure stained with DAI to identify the chromosome.

Figure 12: is an illustration of northern blot analysis of NAALAD-ase II and IV expression. Human multiple tissue Northern blots (Klondike) containing 2 µg per lane of poly (A)+ RNA were hybridised with a

- 15 -

<sup>32</sup>P-labelled NAALAD-ase II (A) or IV (B) probes at 68°C and washed at high stringency (final washes at 50°C with 1/10 dilution of SSC/0.1 % SDS).

5 Autoradiographic exposure was done after 3 to 7 days at -70°C with two intensifying screens. Molecular mass markers are indicated in bp on the left hand side of each autoradiogram.

10 Figure 13: is an illustration of RT-PCR analysis of NAALAD-ase expression in different tissues. PCR amplifications with primers specific for human NAALAD-ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were performed on normalised human MTC cDNAs for 25, 30 and 35 cycles. Images from ethidium bromide stained 1.5% agarose gels were captured using an EagleEye system and EagleSight software (Stratagene). Position control amplifications were performed using the appropriate NAALAD-ase DNA construct. Negative control amplifications contained reaction mix, enzyme and no 15 DNA template. Positive and negative control reactions were performed for 35 cycles. Arrows highlight a specific size in bp as determined using a 100 bp ladder.

20

25 Figure 14: is an illustration of RT-PCT analysis of NAALAD-ase expression in brain areas. PCR amplifications for 25, 30 and 35 cycles, with primers specific for human NAALAD-ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were performed on normalised human 30 cDNAs prepared from dissected brain areas. Images from ethidium bromide stained 11.5 % agarose gels were captured using an EagleEye system and EagleSight software (Stratagene). Results from 30 and 35 cycles of amplification are shown. Positive control 35 amplifications were performed using the appropriate NAALAD-ase DNA construct. Negative control amplifications contained reaction mix and enzyme with

- - 16 -

no DNA template. All control reactions were performed for 35 cycles. Arrows highlight a specific size in bp as determined from the 100 bp ladder.

5      Figure 15: is an illustration of RT-PCR analysis of NAALAD-ase expression in prostate tumour cells. PCR amplifications with primers specific for human NAALAD-ase I (A), L (B), II (C) and IV (D) or GAPDH (E) were performed on normalised cDNAs prepared from cell lines 10 derived from prostate tumours or on prostate tumour. Images from ethidium bromide stained 1.5 % agarose gels were captured using an EagleEye stem and EagleSight software (Stratagene). Results from 25, 30 and 35 cycles of amplification were shown. Positive 15 control amplifications were performed using the appropriate NAALAD-ase DNA construct. Negative control amplifications contained reaction mix and enzyme with no DNA template. All control reactions were performed for 35 cycles. Table 1.

20      Native Taq polymerase and PCR buffer with MgCl<sub>2</sub>, the Expand<sub>TM</sub> long template PCR system, ampicillin, IPTG (isopropyl-β-D-thiogalactoside), X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and all 25 restriction enzymes used were from Boehringer Mannheim (Mannheim, Germany). Super Taq polymerase was from HT Biotechnology (Cambridge, UK). 10 mM dNTP mix was purchased from Life Technologies (Gaithersburg, MD, USA). The original TA cloning kit and the expression 30 vector pCDNA-3 were purchased from Invitrogen BV (Leek, The Netherlands). The Qiagen plasmid mini- and maxi- DNA purification kits, the Qiaquick gel extraction kit and the Qiaquick PCR purification kit were purchased from Qiagen GmbH (Düsseldorf, Germany). 35 Marathon<sub>TM</sub> Ready cDNA kits, MTN cDNA panels and MTN Northern blots were obtained from Clontech Laboratories (Palo Alto, CA, USA). The QuickChange<sub>TM</sub>

- 17 -

Site-Directed Muatagenesis Kit was purchased from Stratagene GmbH (Heidelberg, Germany). All PCR reactions were performed in a GeneAmp PCR system 9600 cycler (Perkin Elmer, Foster City, CA, USA). LB (Luria-Bertani) medium consists of 10 g/l of tryptone, 5 g/l of yeast extract and 10 g/l of NaCl. 2x YT/ampicillin plates consist of 16 g/l of tryptone, 10 g/l of yeast extract, 5 g/l of NaCl, 15 g/l of agar and 100 mg/l of ampicillin.

10

Expressed sequence tag clones.

15

Clone numbers 4190746, 1547649, 3448872, 3608639, 2615389 and 1333965 were ordered from the LifeSeq™ expressed sequence tag (EST) database (Incyte Pharmaceuticals Inc., Palo alto, CA, USA). Samples were delivered as transformed bacterial clones.

20

Oligonucleotide synthesis for PCR and DNA sequencing. All oligonucleotide primers were synthesised by the  $\beta$ -cyanoethylphosphoramidite chemical method on a PerSeptive Biosystems (Framingham, MA, USA) Expedite MOSS Synthesiser or ordered from Eurogentec (Seraing, Belgium). Insert-specific sequencing primers (15- and 16- Mars) were designed manually. DNA was prepared on Qiagen-tip-20 or -100 anion exchange or Qiaquick spin columns (Qiagen GmbH, Düsseldorf, Germany) and recovered from the columns in 30  $\mu$ l TE-buffer (10 mM Tris.HCL, 1 mM EDTA (sodium salt), pH 8.0).

25

Sequencing reactions were done on both strands using the ABI prism BigDye Terminator Cycle sequencing kit and were run on an Applied Biosystems 377XL sequencer (Perkin Elmer; ABI Division, Foster City, CA, USA). The Sequencher™ software was used for sequence assembly and manual editing (GeneCodes, Ann Arbor, MI, USA).

35

Cloning and sequence analysis of NAALAD-ase I, L, II

- 18 -

and IV.

Sequence similarity searching for NAALAD-ase like molecules. Using the complete human (Accession no.M99487), rat (Accession no. RNU75973) and mouse (Accession no. AF026380) NAALAD-ase I protein sequences, the complete rat NAALAD-ase L (GenBank<sub>TM</sub> Accession no AF009921) protein sequence and a partial human NAALAD-ase L protein sequence (GenBank<sub>TM</sub> Accession no. AF010141) as query sequences, a BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990) search was performed on the WashU Merck expressed sequence tag (EST) database and on a proprietary LifeSeq<sub>TM</sub> human EST database (Incyte Pharmaceuticals Inc, Palo Alto, CA, USA). Six EST clones with homology to NAALAD-ase I and L were ordered from the Incyte Pharmaceuticals.

Plasmid DNA preparation and sequencing from Incyte clones. Each Incyte bacterial clone was grown overnight at 37°C in 100 ml LB-medium supplemented with 100 µg/ml of ampicillin. Plasmid DNA was prepared using a Qiagen plasmid midi or maxi kit according to the manufacturer's instructions. The DNA inserts of all clones were completely sequenced on both strands. Clone 4190746 contained sequences corresponding to human NAALAD-ase L and also included likely intronic sequences, clones 133965, 1547649, 3448872, 3608639 contained overlapping DNA sequences coding for a novel protein with some similarity to other NAALAD-ases and clone 2615389 contained DNA sequences corresponding to yet another novel protein with some similarity to previously identified NAALAD-ases. The novel protein sequences derived from these clones were termed NAALAD-ase II and NAALAD-ase IV respectively.

Cloning of NAALAD-ase I by PCR. Sequence data from human NAALAD-ase I (Accession no.M99487) was used to

- 19 -

design primers to amplify the complete coding sequence of NAALAD-ase I by PCR. Primers used were NAALD1S2 (BamHI) = 5'-CCC GGA TCC GAG ATG TGG ATT CTC CTT CAC GAA AC -3' and NAALD1AS2 (XhoI) = 5'- CCC CTC GAG TTA GGC TAC TTC ACT CAA AGT CTC TGC -3' (restriction sites to be introduced are underlined). PCR amplification was performed using Human Marathon-Ready™ cDNA from prostate in a total reaction volume of 50 µl, containing 1X Expand Long Template™ PCR buffer 2, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers NAALD1S1 (BamHI) and NAALD1AS1 (XhoI), 1 µl of Marathon-Ready™ cDNA and 2.5 U of Expand Long Template PCR mix. Samples were pre-heated at 94°C for 5 min before addition of enzyme. Cycling was for 45 s at 94°C, 1 min at 55°C and 1 min 48 s at 68°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel (wt/vol) in 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA (sodium salt), pH 8.3) and the most prominent DNA band was excised from the gel and purified with the Qiaquick gel extraction kit (Qiagen GmbH, Düsseldorf, Germany). The resulting 2303 base pair (bp) fragment was cloned into the plasmid vector pCR2.1 using the original TA cloning kit according to the manufacturer's instructions. Approximately 20 ng of purified fragment was ligated to 50 ng of pCR2.1 plasmid DNA with 4 U T4 DNA ligase in a total volume of 10 µl. Ligations were incubated overnight at 14°C. 2 µl of the ligation reaction was transformed into TOP10F' competent cells using heat-shock transformation and plated on 2x YT/ ampicillin plates supplemented with IPTG and X-gal for blue-white screening. Colony screening was performed on 10 white colonies, from which plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit, and then digested with BAMHI and XHoI. Four clones containing an insert of the appropriate size were sequenced fully. All the

- 20 -

clones had at least one mis-sense PCR error. Clone 10.0 with a single PCR error at position 1183 was used as the template for a site directed mutagenesis (SDM) reaction using the QuickChange™ SDM Kit. Reactions 5 were carried out according to the manufacturer's instructions. Primers designed for the amplification reactions were NAALD1-SDM-S1 = 5'-CCC TCA GAG TGG AGC AGC TGT TGT TCA TGA AAT TGT GAG G -3' and NAALD1-SDM-AS1 = 5' - CCT CAC AAT TTC ATG AAC AAC AGC TGC TCC ACT 10 CTG AGG G -3'. Three white clones from the SDM transformations were screened. Plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit, digested with BamHI and XhoI and sequenced around the mutation site. A single clone 15 (cl.2.0) was sequenced fully on both strands to confirm the complete correct NAALAD-ase I sequence.

Cloning of NAALAD-ase L by PCR and 5' rapid amplification of cDNA ends (RACE) PCR. Sequence data 20 from partial human NAALAD-ase L (GenBank Accession no.AF10141) was used to design primers to amplify the 3' end of NAALAD-ase L by PCR. Primers used were NAALD2S1 = 5' - GTT CTT CAA CAA GCT GCA GGA GCG -3' and NAALD2AS1 (XhoI) = 5' - CCC CTC GAG CCG GAG TAA AGG GAG 25 GGC TGA AG -3'. Human Marathon-Ready™ cDNA from brain, fetal brain, prostate, small intestine, colon were used in the amplification reactions. First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ 30 PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers NAALD2S1 and NAALD2AS1, 1 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 35 45 s at 94°C, 1 min at 58°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE

- 21 -

buffer. Second round PCR amplification was performed with nested primers NAALD2S2 = 5'- GGC GAC CTG AGC ATC TAC GAC AAC -3' and NAALD2AS2 (XhoI) = 5'-CCC CTC GAG TCC CCT CAG AGG TCA GCC ACA G -3'. 1  $\mu$ l of the  
5 first round amplification reaction in a total volume of 50  $\mu$ l containing 1X Expand High FidelityTM PCR buffer, 0.2 mM of each dNTP, 0.2  $\mu$ M each of oligonucleotide primers NAALD2S2 and NAALD2AS2 and 2.5 U of Expand High Fidelity PCR mix. Samples were  
10 preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 45 s at 94°C, 1 min at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1 % agarose gel in 1X TAE buffer and the most prominent  
15 DNA bands were excised from the gel and purified with the Qiaquick gel extraction kit. The resulting fragments 600-800 bp were cloned into CR2.1 as described previously. Ligations were incubated overnight at 14°C and transformed into TOP10F'  
20 competent cells and plated on 2x YT / ampicillin plates supplemented with IPTG and X-gal for blue-white screening. Colony screening was performed on five white colonies from each transformation. Plasmid DNA was prepared from these colonies using the Qiagen  
25 plasmid mini DNA purification kit and then digested with EcoRI. Plasmids containing inserts of the appropriate size were end sequenced using vector primers and then the full sequencing on both strands of putative NAALAD-ase L clones was performed. Clone  
30 6.9 derived from small intestine extended to the translation termination codon.  
To obtain unknown 5' coding sequence for human NAALAD-ase L, two anti-sense primers were designed for 5' rapid amplification of cDNA ends (5' RACE). The  
35 primers were NAALD2AS3 = 5' - GCC AGC ACC CAG AGA ACC CAA G -3' and NAALD2AS4 = 5' -GCT GCG GTT GAA GTA CCG GAT C -3'. Human Marathon-Ready™ cDNA from brain,

- 22 -

fetal brain, prostate, small intestine and colon were used for the 5' RACE according to the manufacturer's instructions. The Marathon-Ready™ cDNA was prepared using oligo-dT priming and a Marathon cDNA adaptor 5 (including two different adaptor-primer annealing sites) ligated to the 5' end of the cDNA. Adaptor-primer AP1 (5' - CCA TCC TAA TAC GAC TCA CTA TAG GGC - 3') and nested adaptor-primer AP2 (5' - ACT CAC TAT AGG GCT CGA GCG GC -3') were included in the kit.

10 First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP1 and NAALD2AS3, 5 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity 15 PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 58°C and 2 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer. Second 20 round 5' RACE was performed using 1 µl of the first round amplification reaction in a total volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP2 and NAALD2AS4 and 2.5 U of Expand High 25 Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were excised from the gel and cloned into the 30 vector pCR2.1 as described earlier. Colony screening by PCR was performed on 60 white colonies in 45 µl PCR mix containing 1X PCR buffer with MgCl<sub>2</sub>, 0.2 mM dNTP, 0.5 µM each of vector primer M13FOR (5'- TGT AAA ACG ACG GCC AGT -3') and M13REV (5' - CAG GAA ACA GCT ATG ACC -3') and 0.35 U of super Taq DNA polymerase. 35 Colonies were picked from the plates, inoculated into 100 µl LB medium supplemented with 100 µg/ml of

- 23 -

ampicillin and incubated for 1 hr at 37°C. 5 µl of the incubated culture was then added to 45 µl PCR mix. PCR was performed for 30 cycles (45 s at 95°C, 1 min at 48°C and 50 s at 72°C). 20 µl of the PCR reactions was analysed on 1% agarose gel in 1x TAE buffer. Clones containing inserts were grown overnight in 3 ml LB medium supplemented with 100 µg/ml of ampicillin and plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit. From the 51 clones sequenced one clone 4.10 contained 258 bp of sequence 5' to NAALD2AS4 of which 70 bp were novel.

The 5' RACE clone (cl. 4.10) and 3' PCR clone (cl. 6.9) were both digested with BamHI. The digested material was run on 1 % agarose gel in 1X TAE buffer. Two bands were excised, a 336 bp band from cl. 4.10 containing all additional 5' RACE DNA sequences and a ~4700 bp fragment containing the remaining 3' NAALAD-ase L and vector sequence from cl. 6.9. The gel slices were purified with the Qiaquick gel extraction kit. The larger of the two fragments was dephosphorylated with 1.5 U calf of intestinal alkaline phosphatase for 1 hr at 37°C and then heat inactivated for 20 min at 75°C, in order to prevent the self ligation of the fragment with itself.

Ligations were performed as described previously and 2µl of the reaction mixture transformed into 35 µl DH10b electrocompetent cells by electroporation (single pulse; 2500V, 25µF 201 W, 5 ms). The electroporated sample was added to 1 ml SOC media and incubated for 1 hr at 37°C before 100 µl of the culture was plated on to 2 x YT/ampicillin plates. Colonies were picked the following day, plasmid DNA prepared and tested by restriction digest. A single clone (cl. 2.0) was fully sequenced on both strands and found to contain the complete 3' coding sequence and the additional sequence from the first 5' RACE reactions. To obtain additional 5' coding sequence

-- 24 --

for the human NAALAD-ase L, two new anti-sense primers were synthesised corresponding to sequences from Incyte clone number 4190746. Primers used were  
NAALD2AS5 = 5'- CTG CAG CTT GTT GAA CTC TTC TGT G -3'  
5 and NAALD2AS6 = 5' CAA ACA CGA TTG ATC TGC GAG GAC -  
3'. Human Marathon-Ready™ cDNA from brain, fetal  
brain, prostate, small intestine, colon and heart were  
used for the 5' rapid amplification of cDNA ends (5'  
RACE) according to the manufacturer's instructions.  
10 First round PCR amplification was performed in a total  
reaction volume of 50 µl containing 1X Expand High  
Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each  
of oligonucleotide primers AP1 and NAALD2AS5, 5 µl of  
Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity  
15 PCR mix. Samples were preheated at 94°C for 5 min  
before addition of the enzyme. Cycling was for 30 s  
at 94°C, 30 s at 58°C and 1 min at 72°C for 30 cycles,  
with a final step of 7 min at 72°C. PCR products were  
analysed on a 1% agarose gel in 1X TAE buffer (40 mM  
20 Tris-acetate, 1 mM EDTA, pH 8.3). Second round PCR  
amplification was performed using 1 µl of the first  
round amplification reaction in a total volume of 50  
MG containing 1X Expand High Fidelity™ PCR buffer, 0.2  
mM of each dNTP, 0.2 µM each of oligonucleotide  
25 primers AP2 and NAALD2AS6 and 2.5 U of Expand High  
Fidelity PCR mix. Samples were preheated at 94°C for  
5 min before addition of the enzyme. Cycling was for  
30 s at 94°C, 30 s at 75°C and 1 min at 72°C for 30  
cycles, with a final step of 7 min at 72°C. PCR  
30 products were analysed on a 1 % agarose gel in 1X TAE  
buffer and the 8 most prominent DNA bands were excised  
from the gel and purified with the Qiaquick gel  
extraction kit. The resulting fragments (400-1300bp)  
were cloned into the plasmid vector pCR2.1 using the  
35 original TA cloning kit. Ligations and transformations  
were performed as described earlier before plating on  
2x YT / ampicillin plates supplemented with IPTG and

-- 25 --

X-gal for blue-white screening. Colony screening was performed on five white colonies from each transformation. Plasmid DNA was prepared from these colonies using the Qiagen plasmid mini DNA kit and 5 digested with EcoRI. Plasmids containing inserts of the appropriate size were end sequenced using vector primers and then the full sequence of putative NAALAD-ase L clones was determined using primer walking. The DNA sequence of five clones, from a 10 small intestine cDNA, extended the coding sequence for NAALAD-ase L in the 5' direction beyond the putative translation start codon and included part of the 5' untranslated region. One of these clones one (cl. 2.2) was used for further experiments.

15 To construct a full length NAALAD-ase L clone, two new primer sets were designed to introduce a unique restriction site (Mun I) into the DNA sequence of NAALAD-ase L without resulting in a change in amino acid sequence or frame shift in the open reading frame 20 (ORF). The first primer set was NAALD2S3 (EcoRV) = 5'- CGG ATA TCC GCA GGA TGC AGT GGA CGA AG -3' and NAALD2AS8 (MunI) - 5'- CAA ACA CAA TTG ATC TGC GAG GAC GC -3' and the second primer set was NAALD2S8 (MunI) = 5'- GCG TCC TCG CAG ATC AAT TGT GTT TG -3' and 25 NAALD2AS1 (XhoI). PCR amplification was performed on 1 $\mu$ l cl. 2.0 plasmid DNA with primers NAALD2S3 (EcoRV) and NAALD2AS8 (MunI) or on 1  $\mu$ l cl. 2.2 plasmid DNA with primers NAALD2S8 (MunI) and NAALD2AS1 (XhoI). Total reaction volumes were as previously described.

30 Samples were preheated at 94°C for 5 min before addition of the Expand High Fidelity enzyme. Cycling was for 45 s at 95°C, 1 min at 57°C and 1 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1 % agarose gel in 1X 35 TAE buffer and TA cloned into pCR2.1 as previously described.

-- 26 --

Splice variant analysis of NAALAD-ase L.

In PCR reactions using NAALAD-ase L specific primers, a number of amplified PCR products were observed of unexpected size. These PCR reactions were repeated  
5 using a number of different cDNAs and bands were excised and purified prior to original TA cloning, as described previously. Plasmid DNA was prepared from these clones and inserts were fully sequenced on both strands in order to identify possible splice variants.  
10

Cloning of NAALAD-ase II by PCR and 5' rapid amplification of cDNA ends (RACE) PCR.

Sequencing results from Incyte clone 3608639 suggested that this clone contained DNA sequence spanning the  
15 complete coding sequence, 2220 bp in size, of a putative NAALAD-ase like molecule (NAALAD-ase II) that had similar sequence to NAALAD-ase I and L. To confirm that there was no possible initiation codon upstream of the initiation codon already determined 5'  
20 RACE PCR was performed. Two anti-sense primers were designed for 5' RACE based on the sequence derived from the clone 3608639, NAALD3AS1 = 5'- CTT TGA TGA TAG CGC ACA GAA GTG G -3' and NAALD3AS2 = 5' GGA AAG ATG CCA GCG CAG GAC 03'. Human Marathon-Ready™ cDNA  
25 from brain, foetal brain, prostate, small intestine and colon were used for the 5' RACE according to the manufacturer's instructions. First round PCR amplification was performed in a total reaction volume of 50 µl containing 1X Expand High Fidelity™ PCR  
30 buffer, 0.2 mM of each dNTP, 02 µM each of oligonucleotide primers AP1 and NAALD3AS1, 5 µl of Marathon-Ready™ cDNA and 2.5 U of Expand High Fidelity PCR mix. Samples were preheated at 94°C for 5 min before addition of the enzyme. Cycling was for 30 s at 94°C, 30 s at 58°C and 2 min at 72°C for 30 cycles, with a final step of 7 min at 72°C. Second round 5'  
35 RACE was performed using 1 µl of the first round

- 27 -

amplification reaction in a total volume of 50 µl containing 1X Expand High Fidelity™ PCR buffer, 0.2 mM of each dNTP, 0.2 µM each of oligonucleotide primers AP2 and NAALD3AS2 and 2.5 U of Expand High Fidelity  
5 PCR mix. Samples were preheated at 94 °C for 5 min before addition of the enzyme. Cycling was for 30 s at 94 °C, 30 s at 57 °C and 1 min at 72 °C for 30 cycles, with a final step of 7 min at 72 °C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer and the  
10 most prominent DNA bands were excised from the gel and purified with the Qiaquick gel extraction kit. The resulting fragments (250 - 600 bp) were cloned into the plasmid pCR2.1 as described previously. 32 white colonies were grown overnight in 3 ml LB medium  
15 supplemented with 100 µg/ml of ampicillin and plasmid DNA was prepared using the Qiagen plasmid mini DNA purification kit. No upstream initiation codon was identified from any of the 32 clones analysed.

20 Cloning of NAALAD-ase IV by PCR.  
Seqencing results from Incyte clone 2615389 revealed that this clone contained partial coding sequence and 3' UTR, of another putative NAALAD-ase like molecule (NAALAD-ase IV) that was related in sequence to  
25 NAALAD-ase I, L and II. The DNA sequence obtained was used in a BLAST search on the Incyte LifeSeq™ EST database. One contig (2519841) was assembled from 150 overlapping Incyte EST sequences that spanned 1881 bp and contained a coding region of 1419 bp. The sequence  
30 data from human NAALAD-ase IV contig 2519841 was used to design primers to amplify the complete coding sequence of by PCR. Primers used were NAALD4SP2 = 5'- CGT CAG AGC CGC CCT ATC AGA TTA TC -3' and NAALD4AP4 = 5'- GAG GAG TTT TCC AAA GTT GCA GAC CC -3'. PCR  
35 amplification was performed using a human hippocampal cDNA in a total reaction volume of 50 µl, containing 1X Expand High FiedlityTM PCR buffer, 0.2mM of each

- 28 -

dNTP, 0.2 µM each of oligonucleotide primers NAALD4SP2 and NAALD4APA4, 1 µl of cDNA and 2.5 U of Expand High FidelityTM PCR mix. Samples were pre-heated at 95°C for 5 min before addition of enzyme. Cycling was for 5 45 s at 94°C, 1 min at 58°C and 35 s at 72°C for 30 cycles, with a final step of 7 min at 72°C. PCR products were analysed on a 1% agarose gel in 1X TAE buffer and the most prominent DNA band was excised from the gel and purified with the Qiaquick gel 10 extraction kit. The resulting 1544 bp DNA fragment was sub-cloned into the plasmid vector pCR2.1-TOPO using the TA TOPO cloning it according to the manufacturer's instructions. Approximately 10 ng of purified fragment was ligated to 10 ng of pCR2.1-TOPO 15 plasmid DNA. Ligations were incubated for 5 min at 25°C. Transformations into TOP10F' competent cells and colony screening was performed as previously described. Three clones containing an insert of the correct size were sequenced fully and two clones were 20 found to contain no PCR errors (cl. 28.0 and cl.1.0).

Activity determinations of NAALAD-ases transiently expressed in COS cells.

Sub-cloning of NAALAD-ases into expression vectors.  
25 NAALAD-ase I, L, II and IV clones were each sub-cloned into the cytomegalovirus (CMV) promoter-based plasmid vector pCDNA-3. NAALAD-ase I/pCR2.1 (cl.2.0) was digested with BamHI/XhoI to excise the complete NAALAD-ase I sequence. NAALAD-ase L-5'/pCR2.1 (cl.2.0) was digested with EcoRV/MunI and NAALAD-ase II-3'/pCR2.1 (cl.2.2) was digested with MunI/XhoI to excise the two halves of complete NAALAD-ase L sequence. NAALAD-ase II/pINCYTE was digested with EcoRI to excise the complete NAALAD-ase II sequence.  
30 NAALAD-ase IV/pCR2.1 (cl.28.0) was digested with HindIII/XbaI to excise the complete NAALAD-ase IV sequence. Fragments were gel-purified and sub-cloned  
35

- 29 -

into dephosphorylated pcDNA3 that had been previously digested with the appropriate restriction enzymes. The resulting expression constructs were verified by complete sequence analysis as described earlier.

5

Transient transfection into COS cells.

COS cells were maintained in complete medium (DMEM supplemented with 10% foetal calf serum, 1X non-essential amino acids and a 1X streptomycin/penicillin/glutamine mix). Prior to transfection cells were washed twice with PBS,  $\text{Ca}^{+2}/\text{Mg}^{2+}$  free pre-warmed to 37°C and dissociated from culture plates by addition of a trypsin/EDTA solution for 1-2 minutes. Cells were collected after a 10 min spin at 1600 rpm and re-suspended in 1-2 ml of equilibrated (5%  $\text{CO}_2$ /95% air) pre-warmed medium. The cell titre was determined in a Coulter counter and cells were seeded in 6 well plates at a density of 15000 cells/cm<sup>2</sup> and allowed to reach approximately 80% confluence (~2 days growth). For each transfection 6 µl FuGENE6 (Boehringer Mannheim, Germany) was added to 96 µl serum free medium and incubated for 5 minutes at 20°C. This preparation was added to a second tube containing 1 µg of NAALAD-ase/pcDNA3 DNA, mixed gently and allowed to stand for 15 minutes at room temperature. The DNA/FuGENE6/serum-free medium mix was pipetted into a well containing 2 ml fresh complete medium. Cells were incubated for 72 hrs in a 37°C incubator before collection.

30

Determination of Biological Activity of NAALAD-ase homologues.

NAALAD-ase activity was quantified by determination of the extent of hydrolysis of N-acetyl-L-aspartyl-L-(3,4-[<sup>3</sup>H])-glutamate as previously described (Blakeley et al., 1988). Transfected COS cell pellets were incubated with 50 mM Tris-HCl (pH7.4)/0.1% Triton X-

- 30 -

100 and vortexed. Homogenates were put through at least one freeze/thaw cycle in liquid N<sub>2</sub> before being used for assay. All assays were formed in a total volume of 200  $\mu$ l containing 50 mM Tris-HCl (pH 7.4), 1  
5 mM Zn<sup>2+</sup>Cl<sub>2</sub>, 500 nM N-acetyl-L-aspartyl-L-(3,4-<sup>3</sup>H)-glutamate ([<sup>3</sup>H]-NAAG) and 10-200  $\mu$ g membrane protein in the presence or absence of 3  $\mu$ M quisqualate / 1% DMSO (vol/vol). Assays were initiated by the addition of the membrane homogenates to the assay mixture,  
10 preincubated at 37°C. The assay mixture was vortexed and incubated at 37°C for various time points. Reactions were terminated by addition of 200  $\mu$ l ice cold 250 mM potassium phosphate and placing the reaction tubes in ice water. After a 5 min  
15 centrifugation step at 14000 rpm, the assay samples were loaded onto 4 cm anion exchange mini-columns (Bio-Rad Agl-X 8) that had been pre-washed with MilliQ water. Columns were rinsed twice with 2 ml MilliQ water, and then twice with 2 ml of 0.5 M formic acid  
20 to selectively elute the [<sup>3</sup>H]-glutamate. The remaining substrate could be eluted with 7.5M formic acid. Assay eluates were diluated with scintillation cocktail (16 ml Ultima Gold XR) and counted in a scintillation counter (Packard). Blanks (not exposed to membranes)  
25 were always subtracted. Inhibition curves were performed under similar conditions with concentrations of quisqualate (QA) ranging up to 300  $\mu$ M. Reactions were followed for 30 min for NAALAD-ase I and for 60 min for NAALAD-ase L and II prior to termination of  
30 the reaction.

SPA development for high throughput screening.  
NAALAD-ase assays were performed at 37°C or 25°C for 10 min in the presence of 50 mM Tris-HCl, pH 7.4,  
35 containing 1 mM ZnCl<sub>2</sub>. Each assay was performed in a 100  $\mu$ l reaction volume containing 40 nM 3[H] -NAAG, 50 mM Tris-HCl (pH 7.4), 1 mM Zn<sup>2+</sup>Cl<sub>2</sub> and either 10  $\mu$ g of

- 31 -

recombinant NAALAD-ase I or LNCaP cell membrane preparations. Reactions were terminated by addition of 100 µl glycine buffer (pH 3.0) and 1 mg naked YS-SPA beads. After allowing the beds to settle for 30  
5 min, the assay mixture was counted in a microtiterplate scintillation counter.

**Chromosomal localisation of NAALAD-ases by FISH.**

Chromosomal mapping studies were carried out by Sidney  
10 Biotech Inc (North York, Ontario Canada) using fluorescent *in situ* hybridisation (FISH) analysis.

Slide preparation. Lymphocytes isolated from human blood were cultured in α-minimal essential medium (MEM) supplemeneted with 10% foetal calf serum and phytohaemagglutinin at 37°C for 68-72 h. The lymphocyte cultures were treated with BrdU (0.18 mg/ml, Sigma Chemical Company, St.Louis, MO, USA) to synchronise the cell population. The synchronised  
15 cells were washed three times with serum-free medium to release the block and re-cultured at 37°C for 6 h in α-MEM with thymidine (2.5µg/ml, Sigma). Cells were harvested and slides were prepared using standard procedures including hypotonic treatment, fixation and  
20 air-drying.  
25

FISH detection: Probes (NAALAD-aseI/pCR2.1 (cl. 2.0) cut with BamHI/XhoI; NAALAD-aseL/pCR2.1 (cl.2.0) cut with XhoI; NAALAD-aseII/pcDNA3 (cl. 3.0) cut with HindIII/XbaI; NAALAD-aseIV/pCR2.1 (cl. 28. 0) cut with HindIII/XbaI; were biotinylated with dATP for 1 h at 150C using the BioNick labelling system (Life Technologies, Gaithersburg, MD, USA). The procedure for FISH detection was performed as previously  
30 described (Heng et al, 1992; Heng & Tsui, 1993). Slides were baked at 55°C for 1 h. After Rnase  
35 treatment, the slides were denatured in 70% formamide

in 2x SSC (20x SSC being 3 M NaCl, 0.3 M sodium citrate, pH 7.0) for 2 min at 70°C followed by dehydration with ethanol. Probes were denatured at 75 C for 5 min in a hybridisation mix consisting of 50% formamide and 10% dextran sulphate. Probes were then loaded on the denatured chromosomal slides. After overnight hybridisation, slides were washed and detected. FISH signals and the DAPI-banding pattern were recorded separately by taking photographs, and the assignment of the FISH mapping data with chromosomal bands was achieved by superimposing FISH signals with DAPI banded chromosomes.

Tissue Distribution of NAALAD-ases.

15 Northern Blot Analysis for NAALAD-ase II and IV. Human MTN Northern blots containing 2 $\mu$ g of poly (A) + RNA derived from non-neuronal tissues were hybridised in ExpressHyb™ hybridisation solution for 2 to 3 h at 68°C according to the manufacturer's instructions. A 20 546 bp NAALAD-ase II fragment was isolated from NAALAD-ase II/pCDNA3 (cl. 3.0) following digestion with EcoRI and BglIII and a NAALAD-ase IV 526 bp fragment was isolated from NAALAD-ase IV/pCR2.1-TOPO (cl. 28 .0) following digestion with PstI.

25 Radiolabelled probes were generated with these DNA fragments using a Rapid Multiprime Labelling kit and [<sup>32</sup>P] - dCTP as label. Following removal of unincorporated label using a Micospin S-200 HR column (Pharmacia), 50  $\mu$ l of hot denatured probe in 6 ml 30 ExpressHyb™ hybridisation solution was incubated in a rotating shaker at 68 C overnight. Washes were 4 x 15 min RT in 2X SSC/0.05% SDS, 1 X 20 min wash at 50 C in 0.1X SSC/0.1% SDS and 2 X 20 min at 55 C in 0.1X SSC/0.1% SDS and 2 X 20 min. Blots were wrapped in 35 cling film, without drying and exposed to X-omat AR Scientific Imaging Film (Kodak Scientific Imaging Systems, Cambridge, UK) for 2 to 4 days at -70°C with

- 33 -

two intensifying screens.

Gene Expression of NAALAD-ase I, L, II and IV by RT-PCR analysis.

5 Oligonucleotide primers designed for the specific amplification of a PCR fragment for each NAALD-ase; NAALAD-ase I primers were NAALAD1S3 5' - GGG AAA CAA ACA AAT TCA GCG GC - 3' and NAALD1AS3 5' GTC AAA GTC CTG GAG TCT CTC ACT GAA C - 3' yielding a 341 bp product, NAALAD-ase L primers were NAALD2S7 5'- GAC CGG AGC AAG ACT TCA GCC AG - 3' and NAALD2AS7 5'- GTG TTG ATA TGC GTT GGC CCA AG - 3' yielding a 330 bp product, NAALAD-ase II primers were NAALD3S4 5' CAC TAA GAA TAA GAA AAC AGA TAA GTA CAG C-3' and NAALD3AS4 15 5'-GAT CAA CTT GTA TAA GTC GTT TAT GAA AAT CTG - 3' yielding a 353 bp product and NAALAD-ase IV primers were NAALD4S1 5' - GCA GAA GAA CAA GGT GGA GTT GGT G- 3' and NAALD4AS1 5' - GCT TTG GAT CCA TGA CAG TCA TGG - 3' yielding a 336 bp product. Each primer set for 20 each NAALAD-ase was tested for its ability to specifically amplify that NAALAD-ase and not to cross react in amplification reactions with the other three forms. PCR amplifications for human GAPDH were performed on the same cDNA samples as positive 25 controls using GAPDH specific primers 5'-TGA AGG TCG GAG TCA ACG GAT TTG GT-3' (sense primer) and 5'- CAT GTG GGC CAT GAG GTC CAC CAC-3' (anti-sense primer), yielding a 1000 bp fragment. These primers sets were used for PCR amplifications on human multiple tissue 30 cDNA (MTCTM) panels normalised to the mRNA expression levels of six different housekeeping genes. Human cDNAs from 15 brain regions were also prepared from mRNA and normalised to the mRNA expression levels of three different housekeeping genes, GAPDH, clathrin 35 and actin. Brain area mRNA was prepared starting from carefully dissected tissue samples, using the FastTrackR 2.0 kit (Invitrogen BV, Netherlands)

- 34 -

according to the manufacturer's instructions. 1 $\mu$ g of poly (A) + RNA was reverse transcribed using oligo (dT) 15 as a primer and 50 U of ExapndTM Reverse Transcriptase (Boehringer Mannheim, Germany)

5 according to the manufacturer's instructions.

Finally, normalised cDNA was prepared in a similar manner from 3 transformed prostate tumour cell lines and a prostate tumour. PCR reactions with NAALAD-ase or GAPDH specific primers were performed on 2 or 5 $\mu$ l 10 of cDNA. PCR reactions were performed in a total volume of 50 $\mu$ l in 1X Advantage PCR buffer, 0.2 mM dNTP and 0.5  $\mu$ M of each PCR primer and 1  $\mu$ l Advantage Taq polymerase mix (95°C -30 sec, 68°C - 1 min 30 s for 35 cycles). Upon completion of 25 cycles the PCR machine 15 was paused at 80C, reaction tubes were removed and 15 $\mu$ l were removed from each PCR tube. Tubes were then returned to the machine and the cycling method continued. Aliquots were removed in a similar manner after 30 and 35 cycles. Each sample taken was 20 analysed by 1.0% agarose gel electrophoresis as previously described and images of the ethidium bromide stained gels were obtained using an Eagle Eye II Video system (Stratagene, La Jolla, CA, USA).

25 Results

Molecular cloning and sequence analysis of NAALAD-ase II, L and IV.

NAALAD-ase L; Similarity searching of the Incyte LifeSeqTM database with the human, rat and mouse 30 NAALAD-ase I sequences and with rat and partial human NAALAD-ase L protein sequences yielded 13 EST sequences, some of which were overlapping, encoding for putatively novel protein sequences similar to NAALAD-ase I and L. DNA obtained from six of the most 35 5' clones were sequenced.

Incyte clone 4190746, from a cerebellar cDNA library contained sequences corresponding to NAALAD-ase L.

- 35 -

However, since this clone also contained two segments of intronic sequence it was not suitable for further cloning experiments. PCR reactions were performed to amplify a PCR product containing the 3' half of the 5 NAALAD-ase L coding region from a small intestine cDNA. To identify the remaining as yet unknown human 5' NAALAD-ase L sequence, 5' RACE PCR was performed on a number of cDNAs. Sequencing of the amplification products obtained from reactions using small intestine 10 cDNA yielded a further 1344 bp fragment covering the complete coding sequence of NAALAD-ase L. The full cDNA sequence contained an open reading frame of 2223 bp encoding a protein of 740 amino acid residues with a calculated molecular mass of 80.6 kDa and an 15 isoelectric point of 5.26 (Fig.1). The putative ATG translation start codon is in a favourable context for translation initiation (Kozak, 1989) with no ATG codons detected upstream. Analysis of the human NAALAD-ase L ORF predicted a type II integral membrane 20 protein containing a single hydrophobic membrane-spanning domain extending from amino acid residues 6-27, with lysine residues bordering either side of the potential membrane-spanning domain (determined by the method of Kyte-Doolittle, 1982). There are 7 25 potential N-glycosylation sites (N X S/T), indicated in Figure 1. The predicted protein sequences of human NAALAD-ase L was compared to that of rat using the alignment program Genedoc. Human NAALAD-ase L sequence was 78% identical and 87% similar to rat 30 NAALAD-ase L. The two protein sequences were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany; Fig.2)

NAALAD-ase II; Incyte clones 1547649, 3448872, 35 3608639 and 1333965 contained sequences originating from the same gene that were similar to but not identical to NAALAD-ase I or L. Clone 3608639, from a

lung carcinoma cDNA library, contained a 3110 bp DNA sequence, with a 2223 bp ORF coding for a 740 amino acid residue protein, which we termed NAALAD-ase II (Fig.4). Analysis of this open reading frame 5 predicted a calculated molecular mass of 83.6kDa and an isoelectric point of 8.53. The putative ATG translation start codon is in a favourable context for translation initiation (Kozak, 1989) and no ATG codons were detected upstream. NAALAD-ase II was predicted 10 to be a type II integral membrane protein containing a hydrophobic membrane spanning domain extending from amino acid residues 8-31 (determined by the method of Kyte and Doolittle, 1982). There are also 7 potential N-glycosylation sites (N X S/T) indicated in Fig.4.

15 NAALAD-ase IV; Sequencing of Incyte clone 2615389, derived from a gall bladder cDNA library, identified sequences originating from a gene with some similarity to NAALAD-ase I and L. Homology searching in the 20 Incyte EST database using this new sequence information identified a contig of over 150 overlapping EST sequences spanning 1884 bp and containing an ORF of 1419 bp, plus 5' and 3' UTRs. Translation of the ORF predicted a 472 amino acid 25 protein with calculated molecular mass of 51.9 kDa and an isoelectric point of 5.99 (Fig.5). We have named this protein NAALAD-ase IV. The putative ATG translation start codon is in a favourable context for translation initiation with no ATG codons detected 30 upstream. Analysis of the NAALAD-ase IV sequence predicted a type II integral membrane protein containing a hydrophobic membrane spanning domain extending from amino acid 3 to approximately 24 with lysine residues found on either side of the potential 35 membrane-spanning domain (determined by the method of Kyte and Doolittle, 1982). There are 5 potential N-glycosylation sites (N x S/T) indicated in Fig. 5.

The predicted protein sequences of NAALAD-ase I, L, II and IV were compared to each other using the alignment program BESTFIT (Wisconsin package, Genetics Computer Group Software, Madison, Wisconsin, USA). The % identity and % similarity between each pair of sequences calculated by the Genedoc program is indicated in Table 1. NAALAD-ase I sequence was 67% identical to NAALAD-ase II, 35% identical to NAALAD-ase L and 10% identical to NAALAD-ase IV. NAALAD-ase L and II were 37% identical. The four protein sequences for NAALAD-ase I, II, L and IV were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany) and are shown in Fig. 6. The highest regions of conservation between these proteins occur in the two predicted catalytic domains. A phylogram of NAALAD-ase I, II, L and IV was constructed using GCG 'Distances' program with standard parameters and the 'Growtree' program with the UPGMA method and is depicted in Fig. 7. From this phylogram it is clear that NAALAD-ase I and II are the most closely related proteins with NAALAD-ase IV being the distant relative.

Two putative catalytic domains have been identified in NAALAD-ase I and L sequences by comparison to other peptidases (Bzegda et al., 1997; Shneider et al., 1997). Using multiple sequence alignments of NAALAD-ase I, II, L and IV we have identified similar putative catalytic domains in human NAALAD-ase II, L and IV (see Fig. 6 and 8). The first catalytic domain is related to bacterial and yeast Zn<sup>2+</sup> dependent peptidase domains (Bzegda et al., 1997). Alignments of these peptidases with NAALAD-ases I, II, L and IV are shown in Fig. 8. All five residues important in Zn<sup>2+</sup> binding are conserved in the NAALAD-ase family.

Additionally, a Glu residue thought to play a role in catalysis is also present. The NAALAD-ase IV sequence, although more distantly related, also shows

statistically significant similarity to the bacterial and yeast amino-peptides Zn<sup>2+</sup> binding domain as determined by the Blastp algorithm (~60% similar, p=10-5). The second catalytic domain is related to members of the α/β hydrolase fold family of proteins (Shneider et al., 1997). Interestingly, there is a conserved nucleophile-acid-base alignment amongst NAALAD-ase I, II and L that may be important in the enzymes catalytic activity (Goossens et al., 1995).

5 Rat NAALAD-ase L has been suggested to belong to an α/β hydrolase fold family of peptidases, similar to dipeptidyl peptidase IV (DPPIV). In contrast, NAALAD-ase IV which is about 270 residues shorter than the other NAALAD-ase proteins lacks this domain.

10

15 Alternative splicing of NAALAD-ase L.  
In the course of the cloning and RT-PCR gene expression analysis of NAALAD-ase L a number of amplified PCR products were observed, isolated and sequenced in order to identify possible splice variants. We found both the splicing out of putative exon sequences, as well as the presence of intronic sequences, as judged by the presence of GT/AG donor/acceptor sites, that were repeatedly amplified  
20 from our cDNA preparations (Fig. 3). When performing 5' RACE amplifications deletions between bases 497-619 and 903-1007 were identified in small intestine and colon that resulted in two in-frame amino acid deletions. In addition a 153 bp intron was found  
25 inserted at base 1094 resulting in an in-frame amino acid insertion of 51 amino acid residues. This insertion is most likely an intron as it has the consensus GT/AG donor acceptor sites at its 5' and 3' ends respectively. In the 3' RACE amplification reactions several variants were also identified in amplifications from small intestine, colon, brain and foetal brain. These consisted of either a deletion of  
30  
35

- 39 -

bases 1525-1615 or a larger deletion between bases 1525-1697. Both these deletions resulted in frame shifts and the premature termination of the protein sequence. Finally, in every cDNA sample examined, two 5 intronic sequences were found to be inserted at either base 1697 and/or at base 1870. Inclusion of one or both of these intronic sequences into the ORF of NAALAD-ase L accounted for the unexpected amplified PCR products migrating at 420 and 500 bp in the RT-PCR 10 experiments. Introduction of one or both these sequences results in a frame shift of the amino acid coding sequence (Fig. 3).

15 Expression and functional activity of NAALAD-ases. To determine if the newly identified NAALAD-ases had peptidase activity, mammalian expression constructs were transiently transfected into COS cells. Membranes from mock transfections were always prepared in parallel as negative controls. Expression of NAALAD- 20 ase I in COS cells was performed as positive control to establish the working conditions of the assay. Fig. 9A shows the amount of [3H]-glutamate in dpms eluted off mini-columns following incubation of [3H]-NAAG with the recombinant NAALAD-ase I. Increasing 25 [3H]-glutamate is eluted from the column in a time dependent manner. Activity was observed for both NAALAD-ase L (data no shown) and NAALAD-ase II (Fig. 9B) suggesting that these enzymes have a similar dipeptidase activity as NAALAD-ase I in this assay. 30 No NAALAD-ase IV dipeptidase activity was observed under these assay conditions. Addition of 30 $\mu$ M quisqualic acid to the reaction inhibited this activity by over 50% after 60 min (Fig. 9A and 9B). Inhibition curves with increasing concentrations of QA 35 were also performed (Fig. 9C) with IC<sub>50</sub> values of 1.2  $\times$  10<sup>-5</sup> M and 1.7  $\times$  10<sup>-5</sup> M for NAALAD-ase I NAALAD-ase II respectively.

- 40 -

A scintillation proximity assay (SPA) was also developed in order to facilitate screening of NAALAD-ase type activity using either the recombinant proteins or membrane preparations from sources known 5 to contain NAALAD-ase activity. A time course of [3H]-NAAG hydrolysis was initially performed using NAALAD-ase I rich LNCaP membrane preparations (Fig. 10A). Stopping the reaction with glycine buffer resulted in binding of the remaining [3H]-NAAG 10 substrate to the SPA beads whereas hydrolysed [3H]-glutamate remained unbound. Therefore as the reaction proceeded and the substrate is hydrolysed, a decrease in signal bound to the beads is observed. Under these SPA conditions, inhibition curves were performed on 15 LNCaP membranes or recombinant NAALAD-ase I membrane preparations using increasing concentrations of QA (Fig.. 10B). The IC<sub>50</sub> values were  $9.1 \times 10^{-7}$  M for LNCaP preparations and  $1 \times 10^{-6}$  M for NAALAD-ase I preparations.

20

#### Chromosomal localisation.

The complete coding sequence of NAALAD-ase I was used as a probe for FISH analysis. Under the conditions used, the hybridisation efficiency was approximately 25 71 % for this probe (among 100 checked mitotic Figures, 71 of them showed signals on one pair of the chromosomes). DAPI banding was used to identify the specific chromosome and an assignment between the signal from the probe and the short arm of chromosome 30 11 was obtained. The detailed position was further determined based upon summary data from 10 photographs (Fig. 11). A weak hybridisation signal was also detected in the region of 11q14.3 with low frequency. With the mapping data obtained from NAALAD-ase II it 35 was concluded that this weak signal was a result of cross-hybridisation (see later) and that NAALAD-ase I is located solely at human chromosome 11, region

p11.21. Example of the mapping results are presented in Fig. 11. For NAALAD-ase L, a 1059 bp fragment (from pos. 1204-2262bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 71 % and DAPI banding was used to identify the signal to the long arm of chromosome 11. The detailed position determined from 10 photographs was on human chromosome 11, region q12 (Fig. 11). For NAALAD-ase II, a 2.5 kb fragment (from pos. 1-2552 bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 74% for this probe. DAPI banding was used to identify the signal to the long arm of chromosome 11. The detailed position determined from 10 photographs was on human chromosome 11, region q14.3-q21 (Fig. 11). For NAALAD-ase IV, a 1539 bp fragment (from pos. 1-1539bp) was used as a probe for FISH analysis. The hybridisation efficiency was approximately 72% for this probe. DAPI banding was used to identify the signal to the long arm of chromosome 8. The detailed position (Fig. 11) determined from 10 photographs was on human chromosome 8, region q21.3.

Tissue distribution of NAALAD-ase III and IV as determined by Northern blot.

The tissue distribution of TrnR3 in different brain regions and in non-neuronal tissues was investigated using RT-PCR, Northern blot analysis and *in situ* hybridization. Northern blot analysis was performed on mRNA derived from different human tissues (Fig.. 12A). A NAALAD-ase II specific probe indicated the presence of transcripts in testis>>>ovary, spleen>prostate, heart and placenta with no signal observed in other tissues. In testis, four transcripts were represented. The most predominant transcript was of approximately 3.4 kb, consistent with the approximate expected size of a NAALAD-ase II message. Two transcripts of 2.4 and 4.4 kb

- 42 -

respectively and a weaker transcript of about 7.5 kb were also present. In the other tissues the 3.4 kb transcript was the only signal detected, apart from ovary where a weak 7.5 kb signal could also be seen.

5      The precise nature of these transcripts awaits further elucidation but may be due to alternative splicing of the message. The nature of these messages is unclear. A NAALAD-ase IV specific probe showed the ubiquitous presence of transcripts in all tissues examined with 10 slightly less signal observed in brain, thymus and testis (Fig. 12B). The most predominant transcript was of approximately 2.2 kb, consistent with the approximate expected size of a NAALAD-ase IV message, with a faint band detected in some tissues at 4.4 kb.

15      Analysis of NAALAD-ase gene expression by RT-PCR. To further examine the detailed tissue distribution of all NAALAD-ases, PCR was performed on normalised cDNAs from 16 different tissues. Figure 13A shows the 20 results from PCR reactions performed with NAALAD-ase I specific primers, yielding amplification products of the expected size (~341 bp). Highest expression of NAALAD-ase I appeared to be in prostate. Rank order of expression after 25 cycles was prostate >>> liver 25 and kidney > small intestine > brain, spleen, with no product amplification observed in the other tissues. At 30 cycles amplification products could be seen in most other tissues with the exception of muscle, blood and thymus in which products could only be observed 30 after 35 cycles of amplification. NAALAD-ase L specific primers yielded a 330 bp amplification product of the expected size, as well as two products migrating with slightly higher sizes of 420 bp and 500 bp (Fig. 13B). NAALAD-ase L expression was highest in 35 small intestine, spleen and testis with PCR products detected after 25 cycles of amplification, whilst products in heart, ovary, colon, blood and prostate

- 43 -

could be seen after 30 cycles. All tissues exhibited some amplification products following 35 cycles with brain and muscle showing the lowest levels. The 420 and 500 bp bands were due to amplification of NAALAD-  
5 ase L sequences containing one or two intronic sequences that were commonly found in all our amplification reactions (see earlier). NAALAD-ase II specific primers yielded a 353 bp amplification product of the expected size (Fig. 13C). NAALAD-ase  
10 II expression was highest in ovary, testis and spleen with PCR products detected after 25 cycles of amplification. After 30 cycles amplification products could be detected from all tissue cDNAs apart from lung, muscle, blood and thymus in which a product  
15 could only be seen after 35 cycles. These results are in good accordance with the expression data obtained with the MTN Northern blots. NAALAD-ase IV specific primers yielded a 336 bp amplification product of the expected size (Fig. 13D). NAALAD-ase IV expression  
20 was low in all tissues with amplification products only detected after 35 cycles. Expression levels were comparable in all the cDNAs apart from brain, lung, muscle and thymus in which no amplification products were clearly visible. Control amplification reactions  
25 using GAPDH specific primers demonstrated comparable levels of amplification products for each cDNA (Fig.13E). Comparison of the relative abundance between the four messages was also possible from these experiments, since the same cDNAs were used for each  
30 set of amplifications. Abundance of NAALAD-ase I message was greater than NAALAD-ase II which was greater than NAALAD-ase L, as judged by the relative amount of amplification products detected at 25 and 30 cycles. NAALAD-ase IV was expressed at the lowest  
35 levels, with PCR products detected only after 35 cycles of amplification.  
PCR reactions were also performed with the same

- 44 -

NAALAD-ase primers as in the above experiments, on 13 different brain cDNAs normalised to the expression levels of three different housekeeping genes. NAALAD-ase I specific amplification products were detected 5 with highest levels of ventral striatum and brain stem after 30 cycles. After 35 cycles NAALAD-ase I specific amplification products could clearly be detected in all brain areas studied (Fig. 14A). NAALAD-ase L specific primers yielded a 330 bp 10 amplification product of the expected size, as well as a product migrating at a higher size of 500 bp (Fig. 14B). Amplification of the 500 bp product was observed after 35 cycles in brain stem, amygdala, thalamus, ventral striatum and to a lesser extent in 15 striatum and hippocampus, whereas the 330 bp product of the expected size was only seen in brain stem and ventral striatum. NAALAD-ase II specific primers yielded a 353 bp amplification product of the expected size (Fig. 14C). Amplification products were observed 20 after 30 cycles in striatum, parietal cortex and ventral striatum with lower levels of amplification product detected in hippocampus, brain stem, putamen and superior colliculus. After 35 cycles the presence of NAALAD-ase II specific products could be detected 25 in all cDNAs apart from inferior colliculus. NAALAD-ase IV specific products could be detected in all brain cDNAs studied after 30 cycles with little difference observed in expression pattern. Levels of amplification products were slightly higher in 30 striatum, hippocampus, brain stem and ventral striatum (Fig. 14D). Control amplification reactions using GAPDH specific primers demonstrated comparable levels of amplification products for each cDNA apart from brain stem which yielded relatively more GAPDH 35 specific product (Fig. 14E). Overall expression of NAALAD-ase L appears to be lower in these brain areas relative to NAALAD-ase I, II and IV.

- 45 -

Finally, NAALAD-ase expression was investigated in cDNAs prepared from either prostate tumour cell lines or a prostate tumour, that had been normalised against three different housekeeping genes. NAALAD-ase I expression was highest in LNCaP and prostate tumour (Fig. 15A). Amplification products were also detected in PC-3 cDNA after 30 and 35 cycles but not in DU145 cDNA. The 330 bp NAALAD-ase L product was detected in highest amounts in cDNA from prostate tumour and less in PC-3 and DU145 samples after 35 cycles (Fig. 15B). Interestingly, in all samples apart from prostate tumour, the higher 500 bp amplification product could be detected. NAALAD-ase II expression was higher in LNCaP than prostate tumour. A faint amplification product could also be detected in PC-3 after 35 cycles but not in DU145 cDNA (Fig. 15C). NAALAD-ase IV expression was highest in LNCaP and prostate tumour (Fig. 15D). Representative amplification with GAPDH primers are also shown (Fig. 15E).

NAALAD-ase I is a type II membrane glycoprotein, with carboxypeptidases activity and sequence similarly to the transferrin receptor (54% identical, Israeli et al., 1993). It may be important in the progression of prostate cancer since it is highly expressed in prostate tumours, and in the CNS it may have an important role in modulating neuronal glutamatergic activity. In this report we describe the identification and cloning of human cDNAs encoding distinct NAALAD-ase enzymes, that represent an expansion of this family of proteins. We have identified in this report two novel members of the NAALAD-ase enzyme family, NAALAD-ase II and NAALAD-ase IV and determined the full coding sequence of human NAALAD-ase L. The degree of divergence of NAALAD-ase L, II and IV at the amino acid sequence level indicates that these are not variants of existing

- 46 -

known genes but new and distinct members of this family. As has been determined for NAALAD-ase I, features common to all three receptors include a hydrophobic leader sequence at the amino-terminus  
5 suitable for secretion, and the presence of several possible N-glycosylation sites. All three novel NAALAD-ases contain a single hydrophobic region of approximately 21 to 24 amino acid residues at their amino-terminus, which is likely membrane spanning, a  
10 short intracellular domain and a large globular extracellular domain. This structure is typical of type II integral membrane proteins and is common amongst membrane bound hydrolases (Kenny et al., 1982). Sequence alignment comparisons of the four  
15 proteins suggests that NAALAD-ase II is most closely related to NAALAD-ase I (81% similar at the amino acid level), whereas NAALAD-ase L is equally similar to both NAALAD-ase I and II (54% similar to both). NAALAD-ase IV is distantly related to the other  
20 members of the family.

Analysis of NAALAD-ase L sequences using different PCR primers sets revealed the presence of multiple splice variants and isoforms. The biological significance or alternatively spliced isoforms of NAALAD-ase L awaits  
25 further clarification. However, the spliced out residues may affect levels of glycosylation and more importantly the conformation and activity of the protein. Furthermore, inclusion of three different intronic sequences identified in amplification reactions from numerous cDNAs, result in either an in-frame addition of a proline rich, 51 amino acid residue, sequence close to the putative catalytic zinc binding domain, or in frame shifts and subsequent premature termination of the NAALAD-ase L protein.  
30 These premature terminations result in elimination of the predicted nucleophile-acid-base arrangement of the putative catalytic site found in  $\alpha/\beta$  hydrolases and

will result in a gross change in the proteins conformation (see Fig. 3). Inclusion of two of the intronic DNA sequences, resulting in frame shifts and premature protein termination, were identified in  
5 nearly all the cDNAs studied, suggesting that expression of these sequences may be used to regulate the levels of active protein. Expression studies using these different splice variants will help to understand the structure/activity relationship of  
10 NAALAD-ase L and help identify which amino acid residues within the protein are important for enzymatic activity. A soluble splice variant of NAALAD-ase I has been reported, lacking the first 40 amino acid residues, including the membrane spanning  
15 domain (Su et al., 1995). An increased ratio of full length protein to truncated protein was observed in malignant prostate tissues, suggesting that expression of alternative splice variants may correlate with tumour progression. Further work will determine if  
20 NAALAD-ase L is involved in oncogenesis and if these splice variants effect tumour progression to differing degrees.

In human tissues, NAALAD-ase I mRNA was highly expressed in prostate but also in liver, kidney and  
25 small intestine and to a lesser extent in brain and spleen. This is partial agreement with Northern blot results obtained in rat in which the highest levels of expression were found to be in brain and kidney but not liver or spleen (prostate was not studied; Bzedga et al. 1997; Carter et al., 1998). NAALAD-ase L expression by RT-PCR was highest in spleen, small intestine and testis. Schneider and colleagues (1997) identified a rat ileal 100 kD protein (I-100; rat  
30 NAALAD-ase L) expressed in rat ileum and human small intestine as seen by Northern blot, but not in testis or spleen. Discrepancies between NAALAD-ase I and L expression patterns could be attributed either to  
35

- 48 -

species differences or the increased sensitivity of mRNA detection by RT-PCR compared to Northern blot hybridisation. NAALAD-ase II mRNA expression was studied both by Northern blot and RT-PCR experiments.

5 Expression experiments using these methods yielded comparable results with the highest levels of mRNA expression being observed in testis and ovary, with less message in spleen, placenta and heart. A number of differently sized transcripts were observed that

10 hybridised to the NAALAD-ase II probe, suggesting the presence of multiple isoforms. It remains to be determined whether these are due to physiologically relevant smaller transcripts or due to problems with the integrity of the mRNA. NAALAD-ase IV mRNA

15 expression was also studied using both techniques and expression data were consistent between the experiments. NAALAD-ase IV expression appeared to be more evenly distributed amongst tissues, with the highest expression in ovary and little or no expression in brain, lung, thymus and testis.

20 Analysis of NAALAD-ase expression in different human brain areas by RT-PCR suggests that NAALAD-ase L is expressed at lowest levels in these brain areas. The amplification products (except those from ventral

25 striatum) migrating at 500 bp were of a higher than expected size and found to contain intronic DNA sequences (see earlier). NAALAD-ase I, II and IV were expressed at the mRNA level in almost all brain areas studied to differing degrees, with highest expression

30 observed in brain stem, striatum, ventral striatum and putamen. In addition, NAALAD-ase II expression appeared relatively more abundant in frontal and parietal cortex. RT-PCR experiments performed on various prostate tumour cell lines and on a prostate

35 tumour sample agreed with reports showing that NAALAD-ase I is expressed in highest amounts in the androgen receptor positive LNCaP cell line (Israeli et al.,

- 49 -

1993). Some amplification products were also observed  
in PC-3 cells after 30 and 35 cycles of amplification,  
in contrast to previous studies detecting no message  
in the androgen receptor negative cells DU-145 and PC-  
5 3 by Northern blotting (Israeli et al. 1993). Since  
low levels of NAALAD-ase actively have been observed  
in these latter two cell lines, some expression of  
these enzymes, including NAALAD-ase I, may occur  
(Pinto et al., 1996). NAALAD-ase II was also  
10 expressed in LNCaP cells at the highest levels,  
whereas NAALAD-ase IV expression was highest in PC-3  
cells. Interestingly, NAALAD-ase I amplification  
products from LNCaP cells were of a higher than  
expected size and contained intronic sequences, in  
15 contrast to the product observed from prostate tumour.  
PC-3 and DU-145 cells yielded both the high and low  
sized amplification products.  
Carboxypeptidase activity of NAALAD-ase I has been  
demonstrated against two classes of substrate in  
20 vitro. The first is based on the enzymes ability to  
hydrolyse x-linked acidic peptides such as N-  
acetylaspartyl glutamate (NAAG) or x-glutamylglutamate  
and the second is based on its ability to hydrolyse γ-  
linked peptides such as folyl-poly-γ-glutamate or -γ  
25 glutamylglutamate. In this study we have expressed  
NAALAD-ase II, L and IV in COS cells and studied the  
ability of these recombinant preparations to hydrolyse  
NAAG. NAALAD-ase I, II and L all showed activity  
against this substrate that was inhibited by QA.  
30 QAIC50s for NAALAD-ase I and II were determined to be  
about 10 μM for both proteins, comparable to that  
described for NAALAD-ase activity in lysed  
synaptosomal membranes (Robinson et al., 1987). The x-  
linked NAALAD-ase hydrolysis of NAAG was initially  
35 characterised in membrane preparations from brain and  
shown to be QA sensitive. Activity was increased by  
divalent cations and inhibited by divalent metal

- 50 -

chelators or general metalloprotease inhibitors (Robinson et al., 1987; Blakely et al, 1988). It was subsequently shown that the enzymatic activity associated with prostate specific marker (PSM, Carter et al., 1996) and rat brain carboxypeptidase II (Luthi-Carter et al., 1998) following transfection experiments, exhibited similar enzyme characteristics to those observed for the QA sensitive NAALAD-ase activity. It has previously been shown that alignment of NAALAD-ase I with zinc amino peptidases from yeast and bacteria identifies a domain of conserved sequences involved in the co-ordination of two zinc ions locate din the catalytic site (Bzedga et al., 1997), Rawlings et al., 1997). The basis for these observations comes from the three dimensional crystal structure of the *Aeromonas proteolytica* zinc aminopeptidase in which residues His 379, Asp 389, Glu 427, Asp 455, His 555 are thought to be involved in the binding of two zinc ions and Glu426 is proposed to be a base residue important in catalysis (Chevrier et al., 1994, 1996). Alignment of the newly identified NAALAD-ases with these amino peptidases (Fig. 8) shows that these zinc binding domains are conserved, suggesting that they may all share the same catalytic mechanism. Bzedga and colleagues (1997) have further suggested that NAALAD-ase I may be a member of the  $\alpha/\beta$  hydrolase fold family because of its dipeptidyl IV and acylaminoacyl peptidase activity, although sequence homology alignments have shown these proteins to be clearly distinct. However, a hypothesised catalytic site arrangement of nucleophile, acid and base (Ser 623, Asp 663 and His 686) is covered and found in NAALAD-ase I, L and II but absent from NAALAD-ase IV (see Fig. 6). The second  $\gamma$ -linked enzymatic activity of NAALAD-ase I to peptides such as pteroyl- $\gamma$ -glutamate (folate hydrolase activity) has been found at high levels in the brush border of human

- 51 -

small intestine (Chandler et al., 1986; Pinto et al., 1996). In addition, carcinoma cells transfected with NAALAD-ase I show increased folate hydrolase activity and the ability to progressively liberate glutamate from methotrexate triglutamate by hydrolysis of  $\gamma$ -glutamyl linkages (Pinto et al., 1996). Indeed, a correlation has been observed between increased pteroyl hydrolases activity and methotrexate resistance in tumours (Banerjee et al., 1986), suggesting that modulating NAALAD-ase activity may be important in developing improved or novel cancer treatments. It will be interesting to determine if these novel NAALAD-ase enzymes with their common secondary structure also have a dual peptidase activity as has been described NAALAD-ase I, and how their structural relationship reflects their activity. Using FISH analysis to determine the chromosomal localisation of NAALAD-ase I, II and L we observed a symmetrical fluorescent signal on chromosome 11, at 11p11.21 for NAALAD-ase I, q12 for NAALAD-ase L and between q14.3-q21 for NAALAD-ase II. In our FISH studies a NAALAD-ase I probe revealed two hybridisation signals, one hybridising at 11p11.21 and another weekly at 11q14.3. This is similar to the results obtain by Leek and colleagues (1995) who observed two hybridisation signals at 11p11.2 and 11q13.5. Having now localised NAALAD-ase II to 11q14.3-q21, it is clear that the second signal is due to cross hybridisation of the NAALAD-ase I probe with the NAALAD-ase II locus. The chromosomal localisation of NAALAD-ase IV revealed a symmetrical fluorescent signal on human chromosome 8 at q21.3, suggesting that this gene is distantly related to the other three genes located on chromosome 11. Chromosome 11 contains a number of genetic disease loci in these regions, including vitreoretinopathy (11q13-q23), xeroderma pigmentosa (11q12-q13), atopy (11q12-q13)

and perhaps more interestingly a tumour suppression locus (11p11.2-p11.13) involved in rat prostate carcinoma. Introduction of this portion of the chromosome into highly metastatic rat prostatic cells 5 was able to suppress cancer metastases without suppression of the *in vivo* growth rate or tumourogenicity of the cells (Ichikawa et al., 1992). Since it has been shown that NAALAD-ase I expression increases with decreasing androgen levels, it is 10 possible that current prostate cancer treatments involving androgen level reduction (e.g. orchidectomy) may work at least in part through alteration of NAALAD-ase expression (Israeli et al., 1994). The enzymatic activity of NAALAD-ase I is similar to that 15 of NAALAD-ase II and L, so it is also conceivable by analogy that these enzymes may also have a role to play in tumour suppression. Interestingly, region 11q13-q23 has also been identified as a region with tumour suppressor activity using tumourgenic 20 HeLa/fibroblast hybrids (Misra and Srivatsan, 1989). In addition, in a systematic analysis of primary cervical carcinomas, region 11q22-q24, was shown to contain tumour suppressor activity (Hampton et al., 1994). These latter two tumour suppressing regions on 25 the long arm of chromosome 11, cover the gene loci of NAALAD-ase L and NAALAD-ase II identified in this study. However, it should be noted that mapping of these tumour suppressing activities to these three chromosomal regions, in no way establishes if any of 30 the identified NAALAD-ases are capable of having tumour or metastatic suppressing activity.  $\alpha$ -NAAG is one of the most abundant peptides in the brain, being present in millimolar concentrations in certain brain regions (see Coyle, 1997). Clarification of the 35 physiological role of NAAG has been difficult as it is co-localised with L-glutamate, but it does fulfil some of the criteria for a neurotransmitter. It is

- 53 -

localised in synaptic vesicles; is realised in Ca<sup>2+</sup> dependent manner from nerve terminals and is rapidly inactivated by a QA sensitive enzyme activity first identified in brain membrane preparations (Robinson et al., 1986, 1987). Cloning experiments revealed the sequence identity of this enzymatic activity to be derived from a previously identified protein, PSM (or NAALAD-ase I, Carter et al., 1996). In this study, NAALAD-ases L and II but not NAALAD-ase IV, have been shown to be able to hydrolyse [3H]-NAAG to N-acetylaspartate and glutamate as has been previously shown with NAALAD-ase I. Given the localisation of these NAALAD-ases in prostate and ovary, as well as other peripheral tissues, it is quite possible that these enzymes may modulate local extracellular glutamate levels in these tissues. For example it is known that substantial amounts of glutamate are present in seminal fluid. In the CNS, NAAG has been shown to act as a partial agonist at the NMDA receptor but not at AMPA or kainate receptors (Vallivullah et al., 1994; Puttfarcken et al., 1993; Sekiguchi et al., 1992) and to attenuate NMDA or glutamate induced neurodegeneration (Bruno et al., 1998). Furthermore, it has also been shown that addition of NAAG to hippocampal slices or mixed cortical cultures results in neuroprotection following addition of excitotoxins via a mechanism distinct from its action of the NMDA receptor. In this case it is postulated that NAAG, which is poorly transported or actively taken up, diffuses from the synaptic cleft and binds as an agonist to type II metabotropic glutamate receptors (mGluR), such as mGluR3, leading to reduced glutamatergic neurotransmission (Wroblewska et al., 1993 and 1997). This hypothesis has been further tested using the mGluR3 antagonist, ethylglutamate, which eliminated the neuroprotective actions of NAAG (Bruno et al., 1998). Although the intact peptide has

- 54 -

predominantly inhibitory actions, another possible mechanism of excitotoxic induced cell death may arise from the aberrant catabolism of NAAG by NAALAD-ases. With endogenous levels of NAAG being so high in brain,  
5 catabolism of NAAG by NAALAD-ases should in theory be a rich source of glutamate, which if not properly regulated may result in excitotoxic effects. Indeed abnormal levels of NAAG or NAALAD-ase activity have been reported in epilepsy (Myerhoof et al., 1985 and  
10 1992), Schizophrenia (Tsai et al., 1995), ALS (Tsai et al., 1991), Alzheimer's disease (Passani et al., 1997a; Jaarsma et al., 1994 and stroke (Sager et al., 1995). Inhibition of NAALAD-ase activities with specific inhibitors may be useful in treating ischemic  
15 induced neurodegeneration or other neurodegenerative disorders involving abnormalities in glutamate neurotransmission, such as Alzheimer's disease, schizophrenia or ALS (Passani et al., 1997b). In vitro at least, the NAALAD-ase (carboxypeptidase)  
20 inhibitor, 2-(phosphonemethyl) pentanedoic acid, inhibited toxicity induced by the carboxypeptidase cleavage of folic acid hexaglutamate (Slusher et al., 1997).

**References.**

Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990). Basic local alignment search tool. *J. Mol. Biol.*, 215, 403-410.

Bruno, V., Wroblewska, B., Wroblewski, J.T., Fiore, L. and Nicoletti, F. (1998) Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. *Neurosci.*, 85(3), 751-757.

Burlina, A.P., Skaper, S.D., Mazza, M.R., Ferrari, V., Leon, A. and Burlina, A.B. (1994) N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro. *J. Neurochem.*, 63(3), 1174-7, 1994.

Bzdega, T., Turi, T., Wroblewska, B., She, D., Chung, H.S., Kim, H. and Neale, J.H. (1997). Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. *J. Neurochem.*, 69, 2270-2277.

Carter, R.E. Feldman, A.R. and Coyle, J.T. (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. *P. Natl. Acad. Sci. USA.*, 93(2), 749-753.

Cassidy, M. and Neale, J.H. (1993) N - acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface or neurons and glia. *Neuropeptides.*, 25(4), 271-278.

Chandler, C.J., Wange, T.T. and Halsted, C.H. (1996) Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterisation.

- 56 -

J.Biol.Chem., 261(2), 928-933.

Chevrier, B., D'Orchymont, H., Schalk, C., Tarnus, C. and Moras, D. (1996) The structure of the *Aeromonas proteolytica* aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu51 and two zinc ions of the co-catalytic unit. Eur.J. Biochem., 237(2), 393-398.

10 Chevrier, B., Schalk, C., D'Orchymont, H., Rondeau, J.M., Moras, D. and Tarnus, C. (1994) Crystal structure of the *Aeromonas proteolytica* aminopeptidase, a prototypical member of the co-catalytic zinc enzyme family. Structure, 2, 283-291.

15 Coyle, J.T. (1997) The nagging question of the function of N-acetylaspartylgutamate. Neurobio. Disease., 4(3-4), 231-238,

20 Ghose, S., Wroblewska, B., Corsi, L., Grayson, D.R., De Blas, A.L., Vicini, S. and Neale, J.H. (1997) N-acetylaspartylgutamate stimulates metabotropic glutamate receptor 3 to regulate expression of the GABA(A)  $\alpha_6$  sub-unit in cerebellar granule cells. J. Neurochem., 69(6), 2326-2335.

25 Hampton, G.M., Penny, L.A., Baergen, R.N., Larson, A., Brewer, C., Liao, S., Busby-Earle, R.M., Williams, A.W., Steel, C.M., Bird C.C., Stanbridge, E.J. and Evans, G.A. (1994) Loss of heterozygosity in sporadic human breast carcinoma, a common region between 11q22 and 11q23.3. P. Natl. Acad.Sci. USA., 91 (6953-6957).

30 Ichikawa, T., Ichikawa, Y., Doing, J., Hawkins, A.L., Griffin, C.A., Isaacs, W.B., Oshimura, M., Barrett, J.C. Isaacs, J.T. (1992) Localisation of metastasis suppressor gene(s) for prostatic cancer to the short

- 57 -

arm of human chromosome 11. *Cancer Res.*, 52(12), 3486-3490.

5 Israel, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the prostate-specific membrane antigen. *Cancer Res.*, 54(7), 1807-1811.

10 Israeli, R.S., Powell, C.T., Fair, W.R. Heston, W.D. (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. *Cancer Res.*, 53(2), 227-230. *J. Neurochem.*, 69(1), 174-181.

15 Jaarsma, D., Veenma-van der Duin, L. and Korf, J. (1994) N-acetylaspartate and N-acetylaspartylgutamate levels in Alzheimer's disease post-mortem brain tissue. *J. Neurol. Sci.*, 127(2), 230-233.

20 Kenny, A.J. and Maroux, S. (1982) Topology of microvillar membrane hydrolases of Kidney and intestine. *Physiol. Revs.* 62(1), 91-128.

25 Kozak, M. (1989) The scanning model for translation, an update. *J. Cell Biol.*, 108, 229-241.

Kyte, J and Doolittle, R.F. (1982) A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.*, 157(1), 105-132.

30 Leek, J., Lench, N., Maraj, B., Baily, A., Carr, I.M., Andersen, S., Cross, J., Whelan, P., MacLennan, K.A., Meredith, D.M. and Markham, A.F. (1995) Prostate-specific membrane antigen, evidence for the existence of a second related human gene. *Brit. J. Cancer*, 72(3), 583-588.

35 Luthi-Carter, R., Berger, U.V., Barczak, A., Enna, J.

Coyle, J.T. (1998) Isolation and expression of a rat brain CdnA encoding glutamate carboxypeptidase II. P. Natl. Acad.Sci. USA., 95(6), 3215-3220.

5 Meyerhoff, J.L., Carter, R.E., Yourick, D.L., Slusher, B.S. and Coyle, J.T. (1992) Activity of a NAAG-hydrolyzing enzyme in brain may affect seizure susceptibility in genetically epilepsy-prone rats. Epilepsy Research (Supp.).., 9, 163-172.

10 Meyerhoff, J.L., Robinson, M.B., Bixler, M.A., Richards, S.S. and Coyle, J.T. (1989) Seizures decrease regionasl enzymatic hydrolysis of N-acetylaspartyglutamate in rat brain. Brain Res., 505(1), 130-134.

15 Meyerhoff, J.L., Koller, K.J., Walczak, D.D. and Coyle, J.T., (1985) Regional brain levels of N-acetylasparty-l-glutamate, the effect of kindled seizures. Brain Res., 346(2), 392-396.

20 Misra, B.C. and Srivatsa, E.S. (1989) Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome 11. Am. J. Hum. Genet., 45(4), 565-577.

25 Orlando, L.R., Luthi-Carter, R., Standaert, D.G., Coyle, J.T., Penney, J.B Jr. and Young, A.B. (1997) N-acetylaspartyglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci. Letts., 236(2), 91-94.

30 Passani, L.A., Vonsattel, J.P. and Coyle, J.T. (1997) Distribution of N-acetylasparty-l-glutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res., 772(1-2), 9-22.

- 59 -

Passani, L.A., Vonsattel, J.P., Carter, R.E. and Coyle, J.T. (1997) N-acetylaspartyl-glutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol., 31(2), 97-118.

10 Pinto, J.T., Suffoletto, B.P., Berzin, T.M., Qiao, C.H., Lin, S., Tong, P.T., May, F., Mukherjee, B. and Heston, W.D. (1996) Prostate-specific membrane antigen, A novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 2, 1445-1451.

15 Puttfarcken, P.S., Handen, J.S., Montgomery, D.T., Coyle, J.T. and Werling, L.. (1993) N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [<sup>3</sup>H] norepinephrine release from rat hippocampal slices. J. Pharmacol. Exp. Ther., 266(2), 796-803.

20 Rawlings, N.D. and Barrett, A.J. (1997) Structure of membrane glutamate carboxypeptidase. Biochim. et Bioph. Acta., 1339(2), 247-252.

25 Robinson, M.B., Blakely, R.D., Couto, R. and Coyle, J.T. (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterisation of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem., 262(30), 14498-14506.

30 Robinson, M.B., Blakely, R.D. and Coyle, J.T. (1986) Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate *in vitro*. Eur. J. Biochem., 130(3), 345-347.

Sager, T.N., Laursen, H. and Hansen, A.J. (1995)

Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. *J. Cerebr. Blood F. Met.*, 15(4), 639-646.

5 Sekiguchi, M., Wada, K. and Wenthold, R.J. (1992) N-acetylaspartylglutamate acts as an agonist upon homomeric NMDA receptor (NMDAR1) expressed in *Xenopusoocytes*. *FEBS Letts.*, 311(3) 285-289.

10 Serval, V., Barbeito, L., Pittaluga, A., Cheramy, A., Lavielle, S. and Glowinski, J. (1990) Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate. *J. Neurochem.*, 55(1), 39-46.

15 Shneider, B.L., Thevananther, S., Moyer, M.S., Walters, H.C., Rinaldo, P., Deverajan, P., Sun, A.Q., Dawson, P.A. and Ananthanarayanan M. (1997) cloning and characterisation of a novel peptidase from rat and human ileum. *J. Biol. Chem.*, 272(49), 31006-31015.

20 Slusher, S, Thomas A.T., Jackson, P.F., Tiffany, C.W. and Suzdak, P.D. (1997) Folate polyglutamate toxicity in rat cortica neurones is attenuated by NAALAD-ase inhibition. *Soc. Neurosci. Abst.*, 23, 898.7.

25 Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston, W.D. (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA, ratio of expression as a potential measurement of progression.. *Cancer Res.*, 55(7), 1441-1443.

30 Tsai, G., Passani, L.A., Slusher, B.S., Carter, R., Baer, L., Kleinman, J.E. and Coyle, J.T. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. *Arch. Gen. Psych.*, 52(10), 829-836.

- 61 -

Tsai, G.C., Stach-Slusher, B., Sim, L., Hedreen, J.C.,  
Rothstein, J.D., Kuncl, R. and Coyle, J.T. (1991)  
Reductions in acidic amino acids and N-  
acetylaspartylglutamate in amyotrophic lateral  
5 sclerosis CNS. Brain Res., 556(1), 151-156.

Valivullah, H.M., Lancaster, J., Sweetnam, P.M. and  
Neale, J.H. (1994) Interactions between N-  
acetylaspartylglutamate and AMPA, kainate, and NMDA  
10 binding sites. J. Neurochem., 63(5), 1714-1719.

Wroblewska B., Wroblewski JT., Saab OH., Neale JH.  
(1993) N-acetylaspartylglutamate inhibits forskolin-  
stimulated cyclic AMP levels via a metabotropic  
15 glutamate receptor in cultured cerebellar granule  
cells. J. Neurochem., 63(3), 943-948.

Wroblewska, B., Wroblewski, J.T., Pshenichkin, S.,  
Surin, A., Sullivan, S.E. and Neale, J.H. (1997) N-  
acetylaspartylglutamate selectively activates mGluR3  
receptors in transfected cells. J Neurochem., 69, 174-  
181.

25

30

Table 1:

	NALAAD-I	NALAAD-L	NALAAD-II	NALAAD-IV
5	NAALAD-I	100	54	81
	NAALAD-L	35	100	54
	NAALAD-II	67	37	100
	NAALAD-IV	10	9	11
				100

Comparison of the predicted protein sequences for  
10 NAALAD-ase I, L, II and IV. The sequences were  
compared two by two using the alignment program  
BESTFIT (GCG package). The obtained values for %  
IDENTITY (upper part of the table) and % similarly  
(lower part of the table) are shown.

15

- 63 -

List of used abbreviations.

	BLAST	basic local alignment search tool
	bp	base pairs
5	CMV	cytomegalovirus
	DMEM	defined minimal essential medium
	EST	expressed sequence tag
	FISH	fluorescent in situ hybridisation
	GAPDH	glyceraldehyde-3-phosphate
10		dehydrogenase
	I100	ileal 100 kDa protein
	IPTG	isopropyl- $\beta$ -D-thiogalactoside
	MEM	minimal essential medium
	NAALAD-ase	N-acetylated alpha-linked acidic dipeptidase
15	NAAG	N-acetyl-L-aspartyl-L-(3,4)-glutamate
	ORF	open reading frame
	PBS	phosphate buffered saline
	PCR	polymerase chain reaction
20	PSM	prostate specific marker
	QA	quisqualate
	RACE	rapid amplification of cDNA ends
	RT-PCR	reverse transcriptioin polymerase chain reaction
25	SDM	site directed mutagenesis
	SPA	scintillation proximity assay
	SSC	sodium chloride sodium citrate
	TAE	Tris acetate EDTA
	X-Gal	5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside
30		

Claims

1. A cDNA molecule encoding a human NAALAD-ase L protein having the amino acid sequence illustrated in figure 1 or a functional equivalent, derivative or bioprecursor thereof.
2. A cDNA molecule according to claim 1 which cDNA comprises the sequence of nucleotides illustrated in Figure 1.
3. A cDNA molecule encoding any of the splice variants of human NAALAD-ase L proteins having the amino acid sequences illustrated in Figure 3.
4. A cDNA molecule according to claim 3 which DNA molecule comprises the sequence of nucleotides illustrated in Figure 1 having respective nucleotide deletions or insertions encoding the respective splice variants of human NAALAD-ase L illustrated in Figure 3.
5. A cDNA molecule encoding a NAALAD-ase II protein having the amino acid sequence illustrated in Figure 4 or a functional equivalent, derivative or bioprecursor thereof.
6. A cDNA molecule according to claim 5 which cDNA molecule comprises the nucleotide sequence illustrated in Figure 4.
7. A cDNA molecule encoding a NAALAD-ase IV protein having the amino acid sequence illustrated in Figure 5 or a functional equivalent, derivative or bioprecursor thereof.
8. A cDNA molecule according to claim 7 having

- 65 -

the nucleotide sequence illustrated in Figure 5.

9. A nucleic acid molecule capable of hybridising to the cDNA molecules according to any of 5 claims 1 and 8 under high stringency conditions.

10. A human NAALAD-ase L protein having an amino acid sequence encoded by the nucleotide sequence illustrated in Figure 1 or a functional equivalent or 10 derivative thereof.

11. A human NAALAD-ase L protein according to claim 10 having the amino acid sequence illustrated in Figure 1 or including the insertions or deletions of 15 the amino acid sequence illustrated in Figure 3.

12. A NAALAD-ase II protein or a functional equivalent, derivative or bioprecursor thereof, encoded by the nucleotide sequence illustrated in 20 Figure 4.

13. A protein according to claim 12 which is a human NAALAD-ase II protein.

25 14. A protein according to claim 12 or 13 having the amino acid sequence illustrated in Figure 4.

30 15. A NAALAD-ase IV protein or a functional equivalent, derivative or bioprecursor thereof, having an amino acid sequence encoded by the nucleotide sequence illustrated in Figure 5.

16. A protein according to claim 15 which is a human NAALAD-ase IV protein.

35

17. A protein according to claim 15 or 16 having the amino acid sequence illustrated in Figure 5.

- 66 -

18. A DNA expression vector which comprises a cDNA molecule according to any of claims 1 to 8.

5 19. A vector according to claim 18 which vector comprises a cytomegalovirus promoter.

20. A vector according to claim 18 or 19 which comprises a sequence encoding a reporter molecule.

10 21. A host cell transformed or transfected with the vector according to any of claims 18 to 20.

22. A host cell according to claim 21 which cell comprises a prokaryotic or eukaryotic cell.

15 23. A host cell according to claim 21 or 22 which is a COS cell.

20 24. A transgenic cell, tissue or organism comprising a transgene capable of expressing a protein according to any of claims 10 to 17.

25 25. A transgenic cell, tissue or organism according to claim 24 wherein said transgene comprises a vector according to any of claims 18 to 20.

30 26. A cDNA or nucleic acid molecule according to any of claims 1 to 9, or a functional equivalent thereof, for use as a medicament.

35 27. Use of a cDNA or nucleic acid molecule according to any of claims 1 to 9, or a functional fragment thereof, in the preparation of a medicament in the treatment of neural diseases including Alzheimer's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to

neurotoxins, peripheral nerve trauma, ischaemia or dementia.

28. A pharmaceutical composition comprising a  
5 nucleic acid or cDNA molecule according to any of  
claims 1 to 8 or a protein according to any of claims  
10 to 17 together with a pharmaceutically acceptable  
carrier, diluent or excipient therefor.

10 29. A method of determining whether a compound is  
an inhibitor or an enhancer of activity of a NAALAD-  
ase protein according to any of claims 10 to 17 which  
method comprises contacting said compound with NAALAD-  
ase protein in the presence of [<sup>3</sup> H] N-acetyl-L-  
15 aspartyl-L-glutamate (NAAG), and monitoring for the  
extent of hydrolysis NAAG compared to a control of  
said NAALAD-ase and NAAG which is not contacted with  
said compound.

20 30. A compound identifiable as an inhibitor or  
enhancer of NAALAD-ase activity according to claim 29.

31. A compound according to claim 30 for use as a  
medicament.

25 32. Use of a compound according to claim 30 in  
the preparation of a medicament for the treatment of  
neural diseases or disorders such as Alzheimer's  
disease, schizophrenia, ALS, Parkinsons disease,  
30 peripheral neuropathy, Huntingdon's disease, acute  
brain injury, multiple sclerosis, exposure to  
neurotoxins, peripheral nerve trauma, ischaemia or  
dementia.

35 33. A pharmaceutical composition comprising a  
compound according to claim 30 together with a  
pharmaceutically acceptable carrier, diluent or

excipient therefor.

34. A method of identifying a compound which is an inhibitor or an enhancer of expression or activity of a NAALAD-ase protein according to any of claims 10 to 17 which method comprises contacting a host cell, tissue or organism expressing said protein with a compound to be tested and monitoring the expression or activity of said protein compared to a control which comprises said cell expressing said protein but which has not been contacted with said compound.

10  
15  
35. A method according to claim 34 wherein said NAALAD-ase expressing cell comprises a host cell according to any of claims 21 to 23 or a transgenic cell, tissue or organism according to claims 24 or 25.

20  
36. A method according to claim 35 wherein said monitoring step comprises monitoring for the expression of said reporter molecule.

25  
37. A compound identifiable as an inhibitor or an enhancer of expression or activity according to the methods of any of claims 34 to 36.

38. A compound according to claim 37 for use as a medicament.

30  
35  
39. Use of a compound according to claim 37 in the preparation of a medicament for treating neural disorders such as Alzheimer's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or dementia.

40. A pharmaceutical composition comprising a

- 69 -

compound according to claim 37 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

5        41. A method of quantifying enzyme activity which method comprises

10      (a) contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof in the presence of SPA beads;

(b) stopping said reaction by adding glycine buffer; and

15      (c) monitoring the signal from said substrate bound to said beads.

20       42. A method of identifying a compound which is an inhibitor or an enhancer of activity of an enzyme, said method comprising;

25      (a) contacting an enzyme of interest with a radiolabelled hydrolysable substrate thereof in the presence of SPA beads and said compound to be tested;

(b) stopping said reaction by adding glycine buffer;

30      (c) monitoring the signal from the substrate bound to said beads compared to a control which has not been contacted with said compound.

35       43. A method according to claim 41 or 42 wherein said substrate comprises [<sup>3</sup>H] NAAG and said enzyme comprises a NAALAD-ase enzyme.

- 70 -

44. A method according to any of claims 41 to 43 wherein said enzyme comprises a NAALAD-ase according to any of claims 10 to 17.

5 45. A compound identifiable as an inhibitor or an enhancer of NAALAD-ase activity according to the method of claims 43 or 44.

10 46. A pharmaceutical composition comprising a compound according to claim 45, together with a pharmaceutically acceptable carrier, diluent or excipient thereof.

15 47. A compound according to claim 45 for use as a medicament.

20 48. Use of a compound according to claim 45 in the manufacture of a medicament for treating neural disorders such as Alzheimers's disease, schizophrenia, ALS, Parkinsons disease, peripheral neuropathy, Huntingdon's disease, acute brain injury, multiple sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or dementia.

09/743647

WO 00/04157

1 / 23

PCT/GB99/02241

500 Recd ST/PTO 12 JAN 2001

THIS PAGE IS A  
BLANK PAGE

09/743647

WO 00/04157

2 / 23

PCT/GB99/02241

*FIG. 1 (CONTINUED)*

CCTCCTGGAGCTCTCCGTCCTGGGCCACCTGGTCTCGAAGAAAGGGACCTGGGTCTCGAGATCAAATCGTTGGAGCTGGGGGC  
L L E L S R V L G T L L K K G T W R P R R S I V F A S W G A 1260

TGAGGAGTTGGGCTCATGGGTCACCGGAATTCAAGAAAGAGTTCTCAACAAGCTGCAGGGGGCACGGGGCTACATCAACGTGGAA  
E E F G L I G S T E F T E E F F N K L Q E R T V A Y I N V D 1350

CATCTCGGTGTTGCCAACGCTACCCTTAAGGTGTCAGGGGACGGCCCTGTCCAGAGGGTGTCTCTCCTAACCAAAAGAGATCCGCTC  
I S V F A M A T L R V Q G T P P V Q S V V F S A T K E I R S 1440

ACCAAGGCCCTGGGACCTTGAGCATTAACGACAACACTGGATCCGGTACTTCACCGCAGCAGCCGGTGTACGGCCCTGGTCCAGCTGGG  
P G P G D L S I Y D N W I R Y F M R S S P V Y G L V P S L G 1530

TTCTCTGGGTGCTGGCAGGACTATGACCCCTCGTTCACTTCCTCCATGGGACATTCCTATACTTATGACCGGAGCAA  
S L G A G S D Y A P F V H F L G I S S M D I A Y T Y D R S K 1620

GACTTCAGGCCAGGATCTACCCACCTACACACAGCCCTTGACACCTTGACTATGTGGACAAGTTTGACCCGGGCTTCAGCAGGCCA  
T S A R I Y P T Y H T A F D T F D Y V D K F L D P G F S S H 1710

TCAGGGCTGGCCCCGGACAGGGGGAGTCTCCGGGTCAAGTGACAGCTCTTCCTGGCCCTCAAGTCAGTGACTACAGTGAGAC  
Q A V A R T A G S V I L R L S D S F F L P L K V S D Y S E T 1800

ACTCCGAGCTTCCCTGAGGGAGCTGGCCAGGAAGATCTGGCCCTGCTGGAGGAGCACAGCATCAGCTGGGTGACTGCAGT  
L R S F L Q A A Q Q D L G A L L E Q H S I S L G P L V T A V 1890

GGAGAACTTTAGGGAGGAAGGCTCAGGCCAACGCAATCAAACTTGAGGAAGGGCAGGCCAACGGCTACAGCTGGGTGAGGTGCT  
E K F E A E A A L G Q R I S T L Q K G S P D P L Q V R M L 1980

CAATGACCAAGTTGATGGCTCTTGGAAACGGACCTTCTGAAACCTTAGAGCCATCTACAGCCATGTGGCTCTGGGACCC  
N D Q L M L L E R T F L N P R A F P E E R Y Y S H V L W A P 2070

TTGGCACGGGCTCCGTAGTCACATTCCGGGGCTATCCAATGGCTGCTCCAGGGCAGGGACACAGCTCTGGATCTGAAGCTGGGCTGA  
S H G L R S H I P G L S N A C S R A R D T A S G S E A W A E 2160

GGCCAGAGACAGCTCACCATGGGTGAGGCTGACACCCCTGAGGGGGCAGCCACCCCTGAGGGCTCTGCTGACCCCTGAGCCCTC  
V Q R Q L S I V V T A L E G A A A T L R P V A D L . 2250

TTCTCTGGCCCTTACTCCGGTCTTTATATTACAAAGTGTCTTAAAGTCTTT 2320

500 Rec'd CT/PTO 12 JAN 2001

THIS PAGE BLANK AS FOLLOWS:

*Fig. 2.*

human	<b>I</b> PFITKVLGLGLGAAALLGLGILGHFAIPKANSL <b>A</b> P----- <b>D</b> PDLDEILETEVINGOLD <b>A</b> IIRIRENLR <b>E</b> LSREP <b>H</b> ILASSPRDEF <b>D</b> L <b>V</b> QL <b>L</b> <b>L</b> <b>Q</b>	: 85
rat	<b>I</b> PHWAKILGLVGIGAAANLLGLGILGHFAIPKATEPLASSVS <b>D</b> S <b>D</b> LD <b>L</b> <b>A</b> IILDSV <b>I</b> NGOLD <b>A</b> IIS <b>R</b> IRENLR <b>E</b> LSREP <b>H</b> ILASSPRDEF <b>D</b> L <b>V</b> QL <b>L</b> <b>L</b> <b>Q</b>	: 90
human	<b>R</b> W <b>K</b> D <b>P</b> E <b>S</b> G <b>L</b> D <b>S</b> <b>A</b> E <b>X</b> <b>I</b> <b>T</b> <b>I</b> <b>V</b> <b>L</b> <b>L</b> <b>S</b> F <b>P</b> S <b>C</b> <b>E</b> <b>Q</b> <b>P</b> <b>M</b> <b>V</b> <b>D</b> <b>I</b> <b>V</b> <b>G</b> <b>P</b> <b>T</b> <b>F</b> <b>C</b> <b>I</b> <b>I</b> <b>H</b> <b>S</b> <b>C</b> <b>H</b> <b>R</b> <b>T</b> <b>E</b> <b>E</b> <b>N</b> <b>V</b> <b>T</b> <b>G</b> <b>C</b> <b>G</b> <b>P</b> <b>D</b> <b>V</b> <b>V</b> <b>Q</b> <b>P</b> <b>Y</b> <b>A</b> <b>A</b> <b>Y</b> <b>A</b> <b>F</b> <b>S</b> <b>G</b> <b>T</b> <b>P</b> <b>O</b> <b>C</b> <b>J</b> <b>L</b> <b>V</b> <b>V</b> <b>A</b> <b>N</b> <b>R</b> <b>G</b> <b>A</b> <b>E</b> <b>D</b> <b>F</b> <b>K</b>	: 175
rat	<b>R</b> W <b>K</b> D <b>S</b> <b>A</b> G <b>S</b> G <b>L</b> D <b>T</b> <b>A</b> K <b>T</b> <b>V</b> <b>L</b> <b>I</b> <b>T</b> <b>V</b> <b>L</b> <b>L</b> <b>S</b> F <b>P</b> S <b>C</b> <b>E</b> <b>Q</b> <b>P</b> <b>M</b> <b>V</b> <b>D</b> <b>I</b> <b>V</b> <b>G</b> <b>P</b> <b>T</b> <b>F</b> <b>C</b> <b>I</b> <b>I</b> <b>H</b> <b>S</b> <b>C</b> <b>H</b> <b>R</b> <b>T</b> <b>E</b> <b>E</b> <b>N</b> <b>V</b> <b>T</b> <b>G</b> <b>C</b> <b>G</b> <b>P</b> <b>D</b> <b>V</b> <b>V</b> <b>Q</b> <b>P</b> <b>Y</b> <b>A</b> <b>A</b> <b>Y</b> <b>A</b> <b>F</b> <b>P</b> <b>G</b> <b>T</b> <b>F</b> <b>R</b> <b>G</b> <b>P</b> <b>L</b> <b>V</b> <b>V</b> <b>A</b> <b>N</b> <b>R</b> <b>G</b> <b>S</b> <b>E</b> <b>D</b> <b>D</b> <b>F</b> <b>K</b>	: 180
human	<b>E</b> LG <b>T</b> <b>G</b> <b>I</b> <b>K</b> <b>L</b> <b>E</b> <b>G</b> <b>T</b> <b>I</b> <b>A</b> <b>L</b> <b>T</b> <b>R</b> <b>Y</b> <b>C</b> <b>G</b> <b>V</b> <b>R</b> <b>G</b> <b>A</b> <b>K</b> <b>A</b> <b>V</b> <b>T</b> <b>A</b> <b>A</b> <b>K</b> <b>H</b> <b>G</b> <b>V</b> <b>I</b> <b>C</b> <b>V</b> <b>L</b> <b>V</b> <b>Y</b> <b>T</b> <b>D</b> <b>F</b> <b>A</b> <b>D</b> <b>I</b> <b>N</b> <b>D</b> <b>G</b> <b>L</b> <b>E</b> <b>S</b> <b>P</b> <b>D</b> <b>E</b> <b>T</b> <b>F</b> <b>P</b> <b>N</b> <b>S</b> <b>W</b> <b>V</b> <b>L</b> <b>P</b> <b>P</b> <b>S</b> <b>G</b> <b>V</b> <b>E</b> <b>R</b> <b>G</b> <b>S</b> <b>Y</b> <b>E</b> <b>Y</b> <b>F</b> <b>G</b> <b>D</b> <b>P</b> <b>L</b> <b>T</b> <b>P</b> <b>Y</b> <b>L</b> <b>P</b> <b>A</b> <b>H</b> <b>F</b>	: 265
rat	<b>E</b> LG <b>T</b> <b>G</b> <b>I</b> <b>K</b> <b>L</b> <b>E</b> <b>G</b> <b>T</b> <b>I</b> <b>A</b> <b>L</b> <b>T</b> <b>R</b> <b>Y</b> <b>C</b> <b>G</b> <b>V</b> <b>R</b> <b>G</b> <b>A</b> <b>K</b> <b>A</b> <b>V</b> <b>T</b> <b>A</b> <b>A</b> <b>K</b> <b>H</b> <b>G</b> <b>V</b> <b>I</b> <b>C</b> <b>V</b> <b>L</b> <b>V</b> <b>Y</b> <b>T</b> <b>D</b> <b>F</b> <b>G</b> <b>D</b> <b>I</b> <b>N</b> <b>D</b> <b>G</b> <b>K</b> <b>S</b> <b>L</b> <b>P</b> <b>N</b> <b>E</b> <b>T</b> <b>F</b> <b>P</b> <b>N</b> <b>S</b> <b>W</b> <b>V</b> <b>L</b> <b>P</b> <b>P</b> <b>S</b> <b>G</b> <b>V</b> <b>E</b> <b>R</b> <b>G</b> <b>S</b> <b>Y</b> <b>E</b> <b>Y</b> <b>F</b> <b>G</b> <b>D</b> <b>P</b> <b>L</b> <b>T</b> <b>P</b> <b>Y</b> <b>L</b> <b>P</b> <b>A</b> <b>H</b> <b>F</b>	: 270
human	<b>S</b> <b>S</b> F <b>R</b> <b>V</b> <b>D</b> <b>L</b> <b>A</b> <b>N</b> <b>V</b> <b>S</b> <b>G</b> <b>F</b> <b>P</b> <b>P</b> <b>I</b> <b>P</b> <b>T</b> <b>O</b> <b>P</b> <b>I</b> <b>G</b> <b>F</b> <b>D</b> <b>A</b> <b>R</b> <b>D</b> <b>L</b> <b>C</b> <b>M</b> <b>L</b> <b>M</b> <b>G</b> <b>T</b> <b>L</b> <b>A</b> <b>P</b> <b>A</b> <b>T</b> <b>W</b> <b>Q</b> <b>G</b> <b>A</b> <b>L</b> <b>G</b> <b>C</b> <b>E</b> <b>Y</b> <b>R</b> <b>L</b> <b>G</b> <b>P</b> <b>G</b> <b>F</b> <b>R</b> <b>P</b> <b>D</b> <b>G</b> <b>D</b> <b>F</b> <b>P</b> <b>A</b> <b>D</b> <b>S</b> <b>Q</b> <b>V</b> <b>N</b> <b>V</b> <b>S</b> <b>V</b> <b>N</b> <b>R</b> <b>E</b> <b>L</b> <b>N</b> <b>S</b> <b>S</b> <b>N</b> <b>V</b> <b>L</b> <b>G</b> <b>I</b> <b>R</b> <b>G</b>	: 355
rat	<b>S</b> <b>S</b> F <b>R</b> <b>V</b> <b>D</b> <b>L</b> <b>A</b> <b>N</b> <b>V</b> <b>S</b> <b>G</b> <b>F</b> <b>P</b> <b>P</b> <b>I</b> <b>P</b> <b>T</b> <b>O</b> <b>P</b> <b>I</b> <b>G</b> <b>F</b> <b>E</b> <b>D</b> <b>A</b> <b>K</b> <b>N</b> <b>L</b> <b>C</b> <b>M</b> <b>L</b> <b>M</b> <b>G</b> <b>T</b> <b>S</b> <b>A</b> <b>P</b> <b>D</b> <b>S</b> <b>W</b> <b>Q</b> <b>G</b> <b>A</b> <b>L</b> <b>G</b> <b>C</b> <b>E</b> <b>Y</b> <b>K</b> <b>L</b> <b>G</b> <b>P</b> <b>G</b> <b>F</b> <b>E</b> <b>P</b> <b>N</b> <b>G</b> <b>N</b> <b>F</b> <b>P</b> <b>A</b> <b>G</b> <b>S</b> <b>E</b> <b>V</b> <b>K</b> <b>V</b> <b>S</b> <b>V</b> <b>N</b> <b>R</b> <b>E</b> <b>L</b> <b>N</b> <b>S</b> <b>S</b> <b>N</b> <b>V</b> <b>L</b> <b>G</b> <b>I</b> <b>R</b> <b>G</b>	: 360
human	<b>A</b> VE <b>P</b> <b>D</b> <b>R</b> <b>V</b> <b>L</b> <b>Y</b> <b>G</b> <b>N</b> <b>H</b> <b>R</b> <b>D</b> <b>S</b> <b>W</b> <b>H</b> <b>A</b> <b>V</b> <b>D</b> <b>P</b> <b>S</b> <b>S</b> <b>G</b> <b>T</b> <b>A</b> <b>V</b> <b>U</b> <b>L</b> <b>E</b> <b>S</b> <b>R</b> <b>V</b> <b>L</b> <b>G</b> <b>T</b> <b>L</b> <b>L</b> <b>K</b> <b>G</b> <b>T</b> <b>W</b> <b>R</b> <b>R</b> <b>S</b> <b>I</b> <b>V</b> <b>F</b> <b>A</b> <b>S</b> <b>W</b> <b>G</b> <b>A</b> <b>E</b> <b>F</b> <b>G</b> <b>L</b> <b>I</b> <b>G</b> <b>S</b> <b>T</b> <b>E</b> <b>F</b> <b>E</b> <b>F</b> <b>M</b> <b>N</b> <b>K</b> <b>Q</b> <b>E</b> <b>R</b> <b>T</b> <b>V</b> <b>A</b> <b>Y</b> <b>I</b> <b>N</b> <b>V</b> <b>D</b>	: 445
rat	<b>A</b> VE <b>P</b> <b>D</b> <b>R</b> <b>V</b> <b>L</b> <b>Y</b> <b>G</b> <b>N</b> <b>H</b> <b>R</b> <b>D</b> <b>S</b> <b>W</b> <b>H</b> <b>A</b> <b>V</b> <b>D</b> <b>P</b> <b>S</b> <b>S</b> <b>G</b> <b>T</b> <b>A</b> <b>V</b> <b>U</b> <b>L</b> <b>E</b> <b>S</b> <b>R</b> <b>V</b> <b>L</b> <b>G</b> <b>T</b> <b>L</b> <b>L</b> <b>K</b> <b>G</b> <b>T</b> <b>W</b> <b>R</b> <b>R</b> <b>S</b> <b>I</b> <b>V</b> <b>F</b> <b>A</b> <b>S</b> <b>W</b> <b>G</b> <b>A</b> <b>E</b> <b>F</b> <b>G</b> <b>L</b> <b>I</b> <b>G</b> <b>S</b> <b>T</b> <b>E</b> <b>F</b> <b>E</b> <b>F</b> <b>M</b> <b>S</b> <b>K</b> <b>Q</b> <b>E</b> <b>R</b> <b>T</b> <b>V</b> <b>A</b> <b>Y</b> <b>I</b> <b>N</b>	: 450

500 Res PCT/PTO 12 JAN 2001.

THIS PAGE BLANK (USPTO)

09/743647

WO 00/04157

4 / 23

PCT/GB99/02241

FIG. 2. (CONTINUED)

human	<b>ISVF</b> <i>A</i> <b>I</b> <b>K</b> <b>T</b> <b>L</b> <b>P</b> <b>V</b> <b>Q</b> <b>G</b> <b>T</b> <b>P</b> <b>V</b> <b>Q</b> <b>S</b> <b>V</b> <b>V</b> <b>T</b> <b>S</b> <b>A</b> <b>T</b> <b>K</b> <b>E</b> <b>I</b> <b>R</b> <b>S</b> <b>P</b> <b>G</b> <b>G</b> <b>D</b> <b>I</b> <b>S</b> <b>I</b> <b>Y</b> <b>D</b> <b>N</b> <b>W</b> <b>I</b> <b>R</b> <b>Y</b> <b>T</b> <b>M</b> <b>R</b> <b>S</b> <b>S</b> <b>P</b> <b>V</b> <b>Y</b> <b>G</b> <b>L</b> <b>V</b> <b>P</b> <b>S</b> <b>L</b> <b>G</b> <b>A</b> <b>G</b> <b>S</b> <b>D</b> <b>Y</b> <b>A</b> <b>P</b> <b>F</b> <b>V</b> <b>H</b> <b>F</b> <b>L</b> <b>G</b> <b>I</b> <b>S</b> <b>S</b> <b>W</b> <b>D</b> <b>I</b> <b>A</b> <b>Y</b> <b>T</b> <b>D</b> <b>R</b> <b>S</b> <b>H</b>	: 535
rat	<b>ISVF</b> <i>S</i> <b>I</b> <b>Y</b> <b>A</b> <b>T</b> <b>L</b> <b>R</b> <b>A</b> <b>Q</b> <b>G</b> <b>T</b> <b>P</b> <b>V</b> <b>Q</b> <b>S</b> <b>V</b> <b>V</b> <b>T</b> <b>S</b> <b>A</b> <b>T</b> <b>K</b> <b>E</b> <b>I</b> <b>S</b> <b>A</b> <b>C</b> <b>S</b> <b>I</b> <b>Y</b> <b>D</b> <b>N</b> <b>W</b> <b>I</b> <b>R</b> <b>Y</b> <b>T</b> <b>M</b> <b>R</b> <b>S</b> <b>S</b> <b>P</b> <b>V</b> <b>Y</b> <b>G</b> <b>L</b> <b>V</b> <b>P</b> <b>S</b> <b>I</b> <b>G</b> <b>T</b> <b>L</b> <b>G</b> <b>A</b> <b>G</b> <b>S</b> <b>D</b> <b>Y</b> <b>A</b> <b>S</b> <b>F</b> <b>I</b> <b>H</b> <b>F</b> <b>L</b> <b>G</b> <b>I</b> <b>T</b> <b>S</b> <b>W</b> <b>D</b> <b>I</b> <b>A</b> <b>Y</b> <b>T</b> <b>D</b> <b>R</b> <b>S</b> <b>H</b>	: 540
human	<b>TSARI</b> <b>Y</b> <b>P</b> <b>T</b> <b>Y</b> <b>H</b> <b>T</b> <b>A</b> <b>F</b> <b>D</b> <b>T</b> <b>F</b> <b>D</b> <b>V</b> <b>D</b> <b>K</b> <b>F</b> <b>L</b> <b>D</b> <b>G</b> <b>F</b> <b>S</b> <b>SH</b> <b>Q</b> <b>A</b> <b>V</b> <b>A</b> <b>R</b> <b>T</b> <b>A</b> <b>G</b> <b>S</b> <b>V</b> <b>I</b> <b>L</b> <b>R</b> <b>L</b> <b>S</b> <b>D</b> <b>S</b> <b>F</b> <b>F</b> <b>L</b> <b>P</b> <b>L</b> <b>K</b> <b>Y</b> <b>S</b> <b>D</b> <b>Y</b> <b>E</b> <b>S</b> <b>T</b> <b>L</b> <b>S</b> <b>F</b> <b>L</b> <b>Q</b> <b>A</b> <b>Q</b> <b>D</b> <b>L</b> <b>G</b> <b>A</b> <b>L</b> <b>E</b> <b>C</b> <b>H</b> <b>S</b> <b>I</b> <b>S</b> <b>L</b> <b>G</b> <b>P</b> <b>L</b> <b>V</b> <b>T</b> <b>A</b> <b>V</b>	: 625
rat	<b>TSARI</b> <b>Y</b> <b>P</b> <b>T</b> <b>Y</b> <b>H</b> <b>T</b> <b>A</b> <b>F</b> <b>D</b> <b>T</b> <b>F</b> <b>D</b> <b>V</b> <b>D</b> <b>K</b> <b>F</b> <b>L</b> <b>D</b> <b>G</b> <b>F</b> <b>S</b> <b>SH</b> <b>Q</b> <b>A</b> <b>V</b> <b>A</b> <b>R</b> <b>T</b> <b>A</b> <b>G</b> <b>S</b> <b>V</b> <b>I</b> <b>L</b> <b>R</b> <b>L</b> <b>S</b> <b>D</b> <b>S</b> <b>F</b> <b>F</b> <b>L</b> <b>Q</b> <b>L</b> <b>U</b> <b>A</b> <b>N</b> <b>S</b> <b>D</b> <b>Y</b> <b>E</b> <b>S</b> <b>T</b> <b>L</b> <b>S</b> <b>F</b> <b>L</b> <b>Q</b> <b>A</b> <b>Q</b> <b>D</b> <b>L</b> <b>G</b> <b>A</b> <b>L</b> <b>E</b> <b>C</b> <b>H</b> <b>S</b> <b>I</b> <b>S</b> <b>L</b> <b>G</b> <b>P</b> <b>L</b> <b>V</b> <b>T</b> <b>A</b> <b>V</b>	: 630
human	<b>EKF</b> <b>E</b> <b>A</b> <b>Z</b> <b>A</b> <b>A</b> <b>L</b> <b>C</b> <b>C</b> <b>P</b> <b>I</b> <b>S</b> <b>T</b> <b>L</b> <b>O</b> <b>N</b> <b>G</b> <b>C</b> <b>P</b> <b>D</b> <b>P</b> <b>L</b> <b>Q</b> <b>V</b> <b>R</b> <b>I</b> <b>N</b> <b>L</b> <b>D</b> <b>Q</b> <b>L</b> <b>H</b> <b>L</b> <b>E</b> <b>F</b> <b>I</b> <b>F</b> <b>L</b> <b>N</b> <b>P</b> <b>R</b> <b>A</b> <b>F</b> <b>P</b> <b>E</b> <b>E</b> <b>R</b> <b>Y</b> <b>Y</b> <b>S</b> <b>H</b> <b>V</b> <b>L</b> <b>M</b> <b>A</b> <b>P</b> <b>S</b> <b>H</b> <b>G</b> <b>L</b> <b>R</b> <b>S</b> <b>H</b> <b>I</b> <b>P</b> <b>G</b> <b>I</b> <b>S</b> <b>M</b> <b>A</b> <b>C</b> <b>S</b> <b>R</b> <b>A</b> <b>D</b> <b>T</b> <b>A</b> <b>S</b> <b>G</b> <b>E</b> <b>A</b> <b>W</b> <b>A</b> <b>E</b>	: 715
rat	<b>EKF</b> <b>E</b> <b>A</b> <b>Z</b> <b>A</b> <b>A</b> <b>L</b> <b>C</b> <b>C</b> <b>P</b> <b>I</b> <b>S</b> <b>T</b> <b>L</b> <b>O</b> <b>N</b> <b>G</b> <b>C</b> <b>P</b> <b>D</b> <b>P</b> <b>L</b> <b>Q</b> <b>V</b> <b>R</b> <b>I</b> <b>N</b> <b>L</b> <b>D</b> <b>Q</b> <b>L</b> <b>H</b> <b>L</b> <b>E</b> <b>F</b> <b>I</b> <b>F</b> <b>L</b> <b>N</b> <b>P</b> <b>R</b> <b>A</b> <b>F</b> <b>P</b> <b>E</b> <b>E</b> <b>R</b> <b>Y</b> <b>Y</b> <b>S</b> <b>H</b> <b>V</b> <b>L</b> <b>M</b> <b>A</b> <b>P</b> <b>S</b> <b>H</b> <b>G</b> <b>L</b> <b>R</b> <b>S</b> <b>H</b> <b>I</b> <b>P</b> <b>G</b> <b>I</b> <b>S</b> <b>M</b> <b>A</b> <b>C</b> <b>S</b> <b>R</b> <b>A</b> <b>D</b> <b>T</b> <b>A</b> <b>S</b> <b>G</b> <b>E</b> <b>A</b> <b>W</b> <b>A</b> <b>E</b>	: 720
human	<b>VRQLSIVWTALEGAAATLRPVADL--</b>	: 740
rat	<b>VRQLSIVWTALEGAAATLQPVIDL--</b>	: 745

500 Recd PCT/PTO 12 JAN 2001

THIS PAGE BLANK (USPTO)

FIG. 5.

MQWTKVLGLGLGAAALLGLGIILGHFAIPKKANSLAPQDLDILETVMQQLDAHRIENLRELSPREPHLASSPRDEDLVQLLLQRWKDP 90

deletion 1 (bp 497-619)



ESGLDSAEAXTYEVLLSFPSQEQPNVDIVGPTGGIIHSCHRTEENVTEQGGPDVVQPYAAYAPSGTPQGLLVYANRGAEDPKELQTQ 180

GIRKLECTIALTRYGGVGRGAKAVNAAKHGVAGVLVYTDPADINDGLSSPDETFPNSWYLPSSGVERGSYYEYFGDPLTPYLPAVPSSFRV 270

```

gtggagcgctacaacccgcctggaaactttccaaacgtccctggccatcatccg
tggggctgtggaggccctggtgagccctccctctgtctgcctgtggcccccgtct
gctctggatgcgcgtgtcctcatccagccctgcaccaccaggcccaagtcctcc
cctgccccacccctcccttccttcgttctgcctcccttccttcgtggccag

```

deletion 2 (bp 903-1007)

DLANVSGFPPIPTQPIGFQDARDLCLCNLNQTLAPATWQCALGCHYRLCGPGFRPDGDFPADSQVNVSYNRLELRNSSLNVLGIIRGAVEP- 359

G-----DRYVLYGNHRDSSVHGAVIDPSSGTAVLLELSRVLCTLK 399

EPSSCCLHPRPPLLCSGCRCPHPALPLPPPSAPPAAHLSSGSLPLFLMP

GTWRFRRSIVFASWGAEEFLIGSTEFFNKLQERTVAYINVDISVFANATLVRQGRPVQSVVVFESATEIERSPGPDLSIYDNWIR 489

2000 PUT/PTO 12 JAN 2001

THE DANCE PIANO

FIG. 3. (CONTINUED)

deletion 3 (bp 1525-1615); deletion 4 (bp 1525-1615)

gtggaggagacaaaggggatccctggagaccatggacggatggactggccctggatccctggccggat

YFNRSSPVYGLVPSLGSLSGAGSDYAPFVHFLGISSMDIAYTYDRSKTSARIYPTYHTAFTFDYVDKFLDPGFSSHQAVARTAGSVILRL 579  
 RLQQPSGCGPDSSGECDSPAQ\*  
 RARTOPGS PPTTQPLTPPLMTMSTPFLTRASAAATRWPGRGCV\*  
 EEGDRKGHPETRTGEAED\*

gtatccacaggccctgaccctggggatcccccatgactggccactgtttccctcacag

SDSFFFLPLKVSODYSETLRSFLQAAQQDGLALEQHNSISLGPLVTAVEKFEABAALGQRISTLOKGSPDPLQVRMLNDQLMLLERFLNPGMHSPPNPFLGAIHPHN\*

R A F P E E R Y S H I V L W A P S H G L R S H I P G L S N A C S R A D T A S G S E A W A E V Q R Q L S I V U T A L E G A A N T L R P V A D L \* 740

500 12 JAN 2001

THIS PAGE BLANK AS OF 12 JAN 2001

09/743647

WO 00/04157

7 / 23

PCT/GB99/02241

FIG. 4.

CTCAGAAGCCATGGGGAAATCCAGGGCGCTCTGTACCTTTGGATGTGCTTGGCTGGCTGGCATCTTCTGATGGGATTATGG  
 M A E S R G R L Y L W M C L A A A L A S F L M G F M V 90  
  
 TGCGCTGGTTATTAAGCCTCTCAAAGAAAACCAACACTCTGTGCGCTATCATCAAAGTATACATCAAAGTATACGGTGGAAACTGGTATCCGAATGAAAG  
 G W F I K P L K E T T S V R Y H Q S I R W K L V S E M K A 180  
  
 C'GAAAACATCAATTCAATTCTCGTTCTAACANGCTTCAATTCTCGTCAATTCTCGTGGGGAAAGAACAAATTCTCTGCTTGCCAAAGAAAATGCC  
 E N I K S F L R S F T K L P H L A G T E Q N F L L A K K I Q 270  
  
 AAACCCAGTGGAGAGAAATTGGACTAGATTCAAGCTGGTCAATTGATGTTCTTACCCAAATGAGACAAATGCCAACT  
 T Q W K K F G L D S A K L V H Y D V L L S Y P N E T N A N Y 360  
  
 ATATATCGATTGTCGATGAAACATGAGATTTCAAAACATCATACCTTGAAACCACCAACAGATGGCTATGAGAATGTTACAAATA  
 I S I V D E H E T E I F K T S Y L E P P P D G Y E N V T N I 450  
  
 V P P Y N A F S A Q G M P E G D L V Y V N Y A R T E D F F K  
  
 TTGTGCCACCATATAATGCTTTCTCAGGCCAAGGCATGCCAGAGGGAGATCTGTATATGTAACATGCTCGCACTGAAGACTATGCTCGTAAACTTTCA  
 540  
  
 L E R E M G I N C T G K I V I A R Y G K I F R G N K V K N A  
  
 AACTAGAAAGAGAGATGGCATCAACTGTACTGGAGATTCTTATGCAAGGATATGCAAGGAAATAAGTTAAAATG  
 CCATGTTAGGAGCCATAGGAATCATCCTTCACTCAGATCCAGCTGACTCTGACTCTGCTCTGAGGTACAGCCATATCCCAGGATGGA  
 M L A G A I G I I L Y S D P A D Y F A P E V Q P Y P K G W N 630  
  
 ATCTTCTGGAACTGCGCCAGAGGAAATCTGTTAAATTGAAATGCTGGTACCCACTCAGGCTATCCAGGAAAGAAT  
 L P G T A A Q R G N V L N L N G A G D P L T P G Y P A K E Y 720  
  
 ACACTTTCAGACTTGATGTTGAAGGAGACTGGAAATCCCCGAATACCTGTACATCCCATGGATAATAATGATGCGAGAAATTATTAC  
 T F R L D V E E G V C I P R I P V H P I G Y N D A E I L L R 810  
  
 GCTACTGGGAGGAATTGGCCACCAAGATAAGAGTTGAAGGGAGCCCTTAATGTGAGTTATAGTATGGACCTGGCTTACAGGGAGCTG  
 Y L G G I A P P D K S W K G A L N V S Y S I G P F T G S D 900  
  
 ATTCTTCAGGAAGGTTAGAAATTCAACATCAATAAAATTACAAGGAAATTACATGTAGTTGAACATCAGAGGATCTGCG  
 S F R K V R M H V Y N I N K I T R I Y N V V G T I R G S V E 1080  
  
 AACCTGACAGGTATGTTATCTGGAGGGTCAACGGGACTTCCTGGGTATTGGAGCTATTGCCCAACCCGCTGGCTGGTGGCAAG  
 P D R Y V I L G H R D S W V F G A I D P T S G V A V L Q E 1170

000100000000 12 JAN 2001

THIS PAGE BLANK REPORT

FIG. 4. (CONTINUED 1)

1260	AAATTGCCGGAGTTTGGAAAACGTGAGCTAGAAGGACCTAGAAGAACTATCATTTCGCCAGCTGGATGCAGAAGGAATTG I A R S F G K L M S K G W R P R T I F A S W D A E E F G
1270	GACTTCGGGTCCACAGAATGGCTGGAGAATGTCAAAATACTCCAGGGAGAGAACCTGCTTATATCAACTCGGATTCATCTATAG I L G S T F W A E E N V K L M S K G W R P R T I F A S W D A E E F G
1280	AAGGCAATTATACTCTCAGAGTAAATCACTGTATGAGCTGACTTCCCCTCTTACCAATTAGTGTNTAAACTGACAAAAATTGCTCTAGAATCAATAAGCTGGGT F E S K S L Y E S W L E K D P S P E N K N L P R I N K L G S
1290	GGTTTGAGAGTAATCACTGTATGAGCTGACTTCCCCTCTTACCAATTAGTGTNTAAACTGACAAAAATTGCTCTAGAATCAATAAGCTGGGT G S D F E A Y F Q R L G I A S G R A R Y T K N K T D K Y S
1300	GCTGGACTGACTTGAAGCTTATTTCAGAGACTTGGCAATTGGCTCAGGGAGGCCGTTACACTAAGGAAATAAGAAAACAGATAAGTACA G S D F E A Y F Q R L G I A S G R A R Y T K N K T D K Y S
1310	GGAGCTACCCAGGTACCAACACATTTAGAGACATTTGAATTGGTAGAGAAATTTTAGACCCCCACATTTTAAACACAACTTTCTCTCG S Y P V Y H T I Y E T F E L V E K F Y D P T F K K Q L S V A
1320	CCTCAATTAGGGGGACTCTGTATATGAGCTCTAAATCATTCTTTAATATTCAAGACTATGAGAAGCTTGAAGCTTGAAGAAACT Q L R G A L V Y E L V D S K I I P F N I Q D Y A E A L K N Y
1330	ATGGAGCAAGTATCTTATCTCTAAAGAAACATGATCAACAAATTACAGGAGCTTACAGTCTTAACTTCAGATTTCAGATTTCAG A A S I Y [N] L S K K H D Q Q L T D H G V S F D S L F S A V K
1340	AAAACCTCTCAGAGGGCTCTCAGATTTCATGATCTTAAACAGACTTATACAGTCTTAACTTCAGATTTCAGCTTAACTTCAGATTTCAG [N] F S E A A S D F H K R L I Q V D L N N P I A V R M M N D Q
1350	AACTGATGCTCTGGAAAAGAGCATTCTGATCCTCTGGTTTACCGGAAAGCTGTCTATAGGCACATCATTTGCTCCAAGTAGGCC L M L L E R A F I D P L G L P G K L F Y R H I I F A P S S H
1360	ACAACNAATACTGGAGAACTCATGATGCTATCTGATATTGAAATAAAACCCAAACTCTCGTTGGCCTGCAAAC N K Y A G E S F P G I Y D A I F D I E N K A N S R L A W K E
1370	AAAGTAAGAAACATATTCTATTGAGCTTACAAATTGAGAAGTATTAGAAGGGCTCAAGGGCTCAAGGGCT V K K H I S I A A F T I Q A A A G T L K E V L :

500 Rad PCT/PTO 12 JAN 2001

THIS PAGE IS A WORK PRODUCT

*FIG. 4. (CONTINUED 2)*

AGCCATTAAAGGTGGCTAAAAGTCTGAGGATAAATTACCTTCTGATAACTTATGAAGCCAGGGTTCTAAACTCTTTCAATGTC	2340
ATGTTTGTATTATAGGCTTCTTCTCATCTCGAAGGCCCTTTTGCTCTTTTAAGTNTAATTTATTTAGCAGACTGTT	2430
AATCTTAATGAACTTCCCTGTGGCAGAAAAGTAAAGAAAATTCCCTAAATTATAGCAAGGAACATGAATTCTCAGACATTCTC	2520
AGTGTGGAAATGTTAAATCTACTTTCAAACAGTTGGCAGTTCTATAAAAGTTAAACATACACTTTTACTTTAGGACTCC	2610
AGAATTCCCACTCTAGTTATTCAAGAGAAAACAATGATCACAGGAATACCTGTTATGCATGTTCAATGCAACTTAAAGGT	2700
AAAAACCCCATAATGTCATCCACAGCCAATGTTGAGACATGTTGAAGGAAAAAGCCAGACAAACAACATATAAAATGAA	2790
GTAACCTTCAATAATGCAATATTATGCCAGACATGTTGAAGGAAAAAGCCAGACAAACAACATATAAAATGTTCTATTAGA	2880
TGAACTGGCAAACTTAATCTGTACTGTAAAATTAGATTAGTGAATTGCCTGGCCAAGTGGCAGGGTGGGGAGGATGGCTGCAAAAGAGT	2970
ATGAGAAAACCTTCTCCAATAGATGCAATTTCGTATCTGACTGTTGAGTGTGCAAAATTGTAACCTTAAATATATAAAATTATTGA	3060
AAGAAAATTAAAGCCTCAATAAACGTGATTATAAAAAAAAAAAAGG	3110

500 Recd PCT/PTO 12 JAN 2001

THIS PAGE BLANK

09/743647

WO 00/04157

10 / 23

PCT/GB99/02241

CGCGCGGGGGCCCCAGGCCCACTGAGGGGTGTGGCTAGCCGCCACCGTAAGGCTAGGCCCGGCCACCGTAAGGCTAGGCCCGAGCTAGTCTGGAGGCCCTCCGTGG	90
TCCTCACCTTTATCCCCTCTGCTCGGAAACCTATATGCCAAGAATGGCATCTCTAGGGACTTCTTGAGGAAATTAGAAATTCCTTATCTCGCATTTCGGTGG	180
V H L S L C S G K A I C K N G I S K R T F E E I K E E I A	270
CAGCTGTGGAGATGTGGCTAAAGCAATCATCAACCTAGCTGTGTATGGTAAGGCCAGAACAGATCCTATGAGGGATTGGCACTTCTGCT	360
S C G D V A K A I I N L A V Y G K A Q <b>N</b> R S Y E R L A L L V	450
TGATACTGTGGACCCAGACTGAGTGGCTCCAAGAACCTAGAAAGCCATCCA AAAATTATGTACCAAAAACCTGAGGAATGGCATTGGCACTTCTGCTGG	540
D T V G P R L S G S K N L E K A I Q I M Y Q N L Q Q D G L E	630
K V H L E P V R I P H W E R G E E S A V M L E P R I H K I A	720
CATCTGGCTCTGGAGCATTGGACTCTCTCCAGAACGCATTACACCCAGAAAGTCTGCTGAGCTCTGGAGGGGAGAAGAATCAGCTGCTGATGAACTGAGAG	810
I L G L G S S I G T P P E G I T A E V L V V T S F D E L Q R	900
ANCGCCCTCAGAACGGGAAGATTGGTGTATAACCAACCCTACATCAACTACTCAAGGACGGTGCATAACCTCACAGTCTCACACAGGTATTCAAGGA	990
R A S E A R G K I V V Y N Q P Y I <b>N</b> Y S R T V Q Y R T Q G A	1080
GGTGCAGGCTCCAGGGCTTGGGCTTGGCATCTCTCATTCAGTCCATCTACAGTCCTCACACAGGTATTCAAGGA	1170
V E A A K V G A L A S L I R S V A S F S I Y S P H T G I Q E	
AATACCGGATGGCTCCAGATTCAACGGCTGATTACGGTGGAGATGAGCTCAAGAAATTGATGTCAGGAGATCAGTGGGAGCAAATATCC	
Y Q D G V P K I P T A C I T V E D A E M M S R M A S H G I K	
AATTGTCTTCAAGATGGGGCAAGAACCTACAGTCTTCAACACTGTAGTGGGCTTGGGAGATGGCTTCTCATGGGATCAA	
I V I Q L K M G A K T Y P D T D S F N T V A E I T G S K Y P	
AGAACAGGGTGTACTGGACATCTGGACAGCTGGGATTTGGGAGGGTGGCCATGGATGATGGGGCTTATATCATG	
E Q V V L V S G H L D S W D V G Q G A M D D G G G A F I S W	
CGGGAAAGCACTCTCACTTATAAGATCTGGCTCGTCCAAAGAGGACTCTGGACTCTGGCTTGGAGAAACAAGGGTGGAGT	
E A L S L I K D L G L R P K R T L V L W T A E E Q G G V	

500 R PCT/PTO 12 JAN 2001

THIS PAGE BLANK

09/743647

WO 00/04157

11 / 23

PCT/GB99/02241

FIG. 5. (CONTINUED)

TGGTGCCTCCAGTATTATCAGTTACACAAGGTAATAATTTCACAACTACAGTCCTGCTGAGCTGACTGACGCCAGGAACCTTCTTACCCAC  
G A F Q Y Y Q L H K V N I S N Y S L V M E S D A G T F L P T 1260  
TGGGTGCAATTCACTCGGCAAGGCCAGGGCCATCATGGAGGGTTATCAGGCCCTGCTGCAGCCCCCTCAATATCACTCAAGTCCT  
G L Q F T G S E K A R A I M E E V M S L L Q P L N I T Q V L 1350  
GAGCCATGGAGAACAGACATCAACTTTGGATTCAGCTGGAGTGCCCTGGAGGCCAGTCTACTTGTACTTGTACTTATAAAGTATTCTT  
S H G E G T D I N F W I Q A G V P G A S L L D D L Y K Y F F 1440  
CTTCCATCACTCCCACGGAGACACCAGTCACTGCTCATGGATCCAAAGCACATGAATGCTGCTGCTGCTGGCTGTGGCTCTATGT  
F H S H G D T M T V M D P K Q M N V A A V W A V V S Y V 1530  
TGTGAGACATGGAAATGCTGCCTAGGTCCCTAGAAAACAGTAAAGAAAACGTTTCACTGGCTCTGGCCAGGAATCTGGGTCTGC  
V A D M E E M L P R S . 1620  
AACTTGGAAAAACTCCTCCATATAACAAATTCACTCCATTTCATGCTTCTGTTATTATCTCTCT  
TGATACTTCCAAATTCTGATTCTAGAAAAGGAATCATTCCTCCCTCCACACATAGAACATAGAACATATGGTAGGGATTACAG 1710  
TGGGGCATTTCTTATATCACCTCTTAAACATTCTTCCACTTTAAAGTAACACTTAAATAAATTTGGAAAGATCTCG  
1800  
1884

12 JAN 2001

THIS PAGE BLANK (USPTO)

FIG. 6.

NAALAD I	MWNLKHETD <del>AVATARPRINCEGAGA</del> VLA-GFFFLGFLFGMPIKSNEATNTPKHN-K-AFDIS-KDENTERKFLYNETQIPLHLAGTEQ	88
NAALAD L	-----MCWTKVLELGIGAAMIGGITLGHPAIPKKANSLAP-----ODDIEJUETVIGDCHRDPENRELEHLSSEPR	75
NAALAD II	-----MAEASRSLRYEWMCUAAFLASFLYGFMWGFIKPKIETTSMRYHQSRWKLVSEVKENGNSFLRSPIKLEHLAGTEQ	78
NAALAD IV	-----MKFLIPAFFGEVHLISLCSGRAICKNGSKRTPEEIKEETIA9CGDVAKATINNAVYGAONRSYELLAFLUDVGEERUSESKN	81

NAALAD I	NAALAD L	NAALAD II	NAALAD IV
<del>NPQLOKQOS OUT - - EFLNSVEJAHDVNLISYE CEDMVQLORNDPESLDEAEXTWLTISFP NFLIAKRIQTQIN - - KFELSAKIVHDLISIP</del>	<del>NKTHPYXISTINEDGNEIINTLPEPEPEVENVSDV GPTGGIHSCHRTEENUTFEQQDGVQEXANAPSC SDEHETEIPKTEXLEPEDEVENTRIPENNTY</del>	<del>PEPBASPOSEPESDUM 176 165 166</del>	<del>PEPBASPOSEPESDUM 176 165 166</del>
<del>LEKAHQIYONLQ - - DEERKVDPURPHMERGYEAVMOPRIKHTAI GEGSIGTEE</del>			

NAALAD I	VNYARTEDDFERKIERD KINCGKATVYAPKFERGNEVKPAQIAKAEVINYBDEADYEPAGK9---YEDMINNTEGGGVRENTNLNG	2.63
NAALAD L	ARG- AEDDFERLQTOGKLESTVNTPLIGGGRGAIAUHAKHEVAEVLVITLUEAINDGJ9SPDETTEPNMVEPPGVERESYYEY--	2.52
NAALAD II	VNYARTEDDFERKIERGNCKETLAPSKIFRGN2URMLAFAEITLISIDEALYAPEVQP---YEKSPLNNGTAAQRENVNLN	2.53
NAALAD IV	--IATAEVWVOTSPDEIVORPASE-ARGK---EUVVNOEKINYRTVQY---RTGAAVEAARGVGLASMRSA	2.08

NAALAD I	AEDBITEGYPANEIATRIGIAEA FGBLITPEAUPSSPRUCHANVSE AEDBITEGYEAKETENDVEEGVE 9FSIISYSPITGQENQD-	VHIEGIVESTVPE PPPIFTQPIGE VHIEGIVENDVE EXERIETACITVEDA	RESKVPE PADSQDN KREKAI TIVEDA	STOKURK N3YNR N3YNNIN MSRMAS	350 341 340 268
NAALAD L	AEDBITEGYPANEIATRIGIAEA FGBLITPEAUPSSPRUCHANVSE AEDBITEGYEAKETENDVEEGVE 9FSIISYSPITGQENQD-	VHIEGIVESTVPE PPPIFTQPIGE VHIEGIVENDVE EXERIETACITVEDA	RESKVPE PADSQDN KREKAI TIVEDA	STOKURK N3YNR N3YNNIN MSRMAS	350 341 340 268
NAALAD II	AEDBITEGYPANEIATRIGIAEA FGBLITPEAUPSSPRUCHANVSE AEDBITEGYEAKETENDVEEGVE 9FSIISYSPITGQENQD-	VHIEGIVESTVPE PPPIFTQPIGE VHIEGIVENDVE EXERIETACITVEDA	RESKVPE PADSQDN KREKAI TIVEDA	STOKURK N3YNR N3YNNIN MSRMAS	350 341 340 268
NAALAD IV	AEDBITEGYPANEIATRIGIAEA FGBLITPEAUPSSPRUCHANVSE AEDBITEGYEAKETENDVEEGVE 9FSIISYSPITGQENQD-	VHIEGIVESTVPE PPPIFTQPIGE VHIEGIVENDVE EXERIETACITVEDA	RESKVPE PADSQDN KREKAI TIVEDA	STOKURK N3YNR N3YNNIN MSRMAS	350 341 340 268

NAALAD I	<b>EVRTRIPLISTLREAVEDRYVITIGENHRDST-</b>	<b>-VP-EGIDEFOREVAVEHETIVSFETUKKEE-</b>	<b>-TIREKKTILFASMDDEERESTLGSTMELAE</b>	437
NAALAD L	<b>EVTRNSMPLLEIREAVERDRVLYRMRHDST-</b>	<b>-VP-SRPLSSE-TAVILLESRVLTLLKRE-</b>	<b>-TIRPRRSVTPASMGAEFFELIGSTEETEE</b>	429
NAALAD II	<b>KSTRTRIPLVETLIRESVUEPDRYVILYRHDST-</b>	<b>-VP-SLIDETEVAVTQELARSFESKUMRE-</b>	<b>-TIRPRRTIPASMDDEERESTLGSTMELAE</b>	427
NAALAD IV	<b>-----ENTVATELIRESKYEEQVWLYSGHLDSDUGOAEMLEDGGA-</b>	<b>-TIREPKTILREVLTREEQGUGAFAYY-K</b>	<b>-TIREPKTILREVLTREEQGUGAFAYY-K</b>	349

**SUBSTITUTE SHEET (RULE 26)**

2000 RELEASE UNDER E.O. 14176 12 JAN 2001

**THIS PAGE BLANK (SPTO)**

## FIG. 6. (CONTINUED)

NSALLOQBERGQUALITYASSETEGY  
PPNOMBERTVANWISWPANVLRVOGN  
NVRGERSLAVIISUSSENEGEGYPLD  
LHVNINENSYLVESSAGTPIPTGQPTG  
NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

SUBSTITUTE SHEET (RULE 26)

NSALLOQBERGQUALITYASSETEGY  
PPNOMBERTVANWISWPANVLRVOGN  
NVRGERSLAVIISUSSENEGEGYPLD  
LHVNINENSYLVESSAGTPIPTGQPTG  
NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

NSALLOQBERGQUALITYASSETEGY  
PPNOMBERTVANWISWPANVLRVOGN  
NVRGERSLAVIISUSSENEGEGYPLD  
LHVNINENSYLVESSAGTPIPTGQPTG  
NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV


NSALLOQBERGQUALITYASSETEGY  
PPNOMBERTVANWISWPANVLRVOGN  
NVRGERSLAVIISUSSENEGEGYPLD  
LHVNINENSYLVESSAGTPIPTGQPTG  
NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

NAALAD I  
NAALAD L  
NAALAD II  
NAALAD IV

JOHN EGYPTO 12 JAN 2001

THIS PAGE BLANK PLEASE.

FIG. 7



THIS PAGE BLANK (USPC)

NAALAD I DAQKLL[EKNGGSAPPD-SSURGSLKV[PINVGPGFTGNF---STQKVRK[HISTNEVTRIYWIGTIREAEPDRWINGG  
 NAALAD L DAEILLRVLGGIAPPD-KSURGALAVS[SIGPGFTGSD---SFRKVREHVYNINKITRIYWUGTIRESVEPDRVILGG 366  
 NAALAD II --RDLLC[NLNGTLAP--ATWOGALGCCYRLGPGRPDGFPA[DSQVNNSVYNRLERNSSAV[EGIIWGAVEPDRYLYNN 367  
 NAALAD IV SPHTGQEQYDGVPKIPTACITVEDAEMHSRMASHGIC---IVIOLKGAKTYPDTS-FNTVAE[TESKYPEQWVLWSG 289  
 APE 3 yeast -----TKHTVATGVCP[KVGKKLIANALNIDSYSLYAMDSYVEFIKTQNLIAADTKHG-DPINWMLGA 313  
 P96152 QINTTIRALSSFNNRFYTASGAQASD[LANEVRSLSI---SLPGSRIEQIKHSGYNO-KSVVLTQSEKPIDEVWINGG 199  
 AMPX vibpr QITGTISLLESFTNRFYTTSGAQASD[IASEUQALSA---SLPNASVKQVSHSGYNO-KSVVMTTSEAFDEWINGG 202  
 APX Strgr -----NNGGNR--AHGRPGYKASVUDVYKAKDA---GYTTTQQFTSGGATG-YMLIANUPEG-DPNKVLMLSA 84

NAALAD I [HRDSU-WF---[F-I-DPQEC-H-AV-VHEETVRSFGTL-KKEG-WRPRRTILE[ASWDREEFGLLGSTEWA-EE-NS 439  
 NAALAD L [HRDSU-WF---[S-AI-DPTBG-V-AV-LQEJASFSFGKL-KSKG-WRPRRTI[ISWDREEFGLLGSTEWA-EE-NS 429  
 NAALAD II [HRDSU-WH---[AV--DPSECTDVL-L-ELSEV[GLTLK-KGTRPRREIVEASMGREEFGLLGSTEWT-EFFFN 432  
 NAALAD IV [HRDSU-WD---[FCA[MDDGGE-[FISU-EALSU]----KDLG-IRPERTLRLVLTAAEQQCY/GAFQVY-QLHKV 352  
 APE 3 yeast [HSDS-WEE---[EPGINDDGGCTISL-L-NVAQCLTH----F[INNNKVR[IA[MAEEEGLLGSMFAYNL TKE 375  
 P96152 [HLDST-LGSHTNEQSIAPEADDIASIESU-S-ELIIVL----RDNN-FRTERSIALMAYAEEVSLRGSDQPA-NQYKA 270  
 AMPX vibpr [HLDST-LGSHTNEQSIAPEADDASGIRAV-T-ELIIVL----SENN-FQPERSTIAUHAYAEEVGLRGSDLA-NQYKS 273  
 APX Strgr [HLDSt-WSS---[AGINDNC[GSDAV-L-ETALAY----SRAG-YQFDKHLRFJUNGCREELGLIGSKF[V-NNLPS 147

NAALAD I RLLQFERGVAYINASSI-EGNYTLRDC[PLMYSLVHNL[KEIKSPDGFEGKS]YESUTKKS--PSPEFGMPRISKLS 516  
 NAALAD L KILOFEESIAYINASSI-EGNYTLRDC[PLLYQLVYKL[KEIPSPDDGFESKS]YESULEKD--PSPENKNLPRIMKL 506  
 NAALAD II KL-QEFTVAYINNUISV-FANATLRQGJPPVQSVVFSAKEI[RSPPGPGD--LSIYDNEIRYFNRSSPVYGLVPSLGSLS 508  
 NAALAD IV NIS--NYSLVWESAGT-FLPTGLOFTGSEKARA---INEEUM-----SILQPLNITO-----VLSH[ 404  
 APE 3 yeast ENSKIR--VFIDYDMM-SPNEYEYDANNKENP--KGFEELK-----NAYVVDYKAH-----HLNYNTLVPFDG 415  
 P96152 QGK--KVVSVULQD[MTYRGSAEDINFIDYTD[---NLQF[ T-----TLEIDEVLP[EL-----TYG----YDRCS 327  
 AMPX vibpr EGK--NVVSALQD[MTYKGSAQDV[ FIDYTD[---NFQYQ[ T-----QLMDE[ LPSL-----TYG----FDTCC 330  
 APX Strgr AD-RSFLAGT[MFDE-IGSPNP[GYFYDDDPVIEK--TFKNYFA[G-----LNVPTELETE-----GDGRSDHAPFKN 210

500 Re N PCT/PTO 12 JAN 2001

THIS PAGE BLANK as per

*FIG. 8. (CONTINUED)*




NAALAD I	SGNDFEVFFORLRLIASGRARYTENWETNKFSGYPLIYEVETYELVEK-----	582
NAALAD L	SGSDFEAAY[RE]ORLRLIASGRARYTENKKTDKYSSSYPTVY[RE]IYEFELVEK-----	572
NAALAD II	AGSDYAPFVHFL[RE]ISSMDIAITYDRSKTSARIYPTVY[RE]AFDIFDYNDK-----	574
NAALAD IV	EGTDIN-FEIQAGVPGASLLDDLYKYFF-----FHSHHGDUIMTVEDPKQMNVAAVLAVVSYYVNDMEEMLPRS-----	472
AP <sub>E</sub> 3 yeast	RSDYUGFINNCGIPAGGIATGAEMNNVNNGKVLDRCYHQLCDDVSMSISUDAFITNTKLIAHSVATYDSEFGFPKRETQKH-----	515
P96152	YACSDHASETHKA[GFSAAAMPFESIKFDYN-----PKIHESSQDLANSDPY-----	391
AMPX vibpr	YACSDHASEHNAGYPAAAMPFESIKFDYN-----PRHTQDTLANSDPY-----GSHAKR[RE]TQLGLAY[RE]IENGGS-----	394
APX Strgr	VGVPVUGGLITGAA[RE]YTKSAAQAGMUGGTAGQA[RE]FDRCYHSSCDSLMS[RE]NTALDRNSDAAAAHAIUTLSSGTGEPP-----	294

500 Rec'd CT/PTO 12 JAN 2001

**THIS PAGE BLANK**

**A**

FIG. 9.


**B****C**

500 Rec'd PCT/PTO 12 JAN 2001


THIS PAGE BLANK (USPTO)

FIG. 10.

A



B




500 Rec PCT/PTO 12 JAN 2001


THIS PAGE BLANK (USPTO)

FIG. 11.


A





C



E



G



500 Re 1 PCT/PTO 12 JAN 2001

THIS PAGE IS DAMAGED

09/743647


WO 00/04157

20 / 23


PCT/GB99/02241

FIG. 12.

A



B



500 R PCT/PTO 12 JAN 2001

THIS PAGE BLANK (USPTO)

09/743647


WO 00/04157

21 / 23


PCT/GB99/02241

FIG. 13.


A




B




C



D



E



500 Rec. CT/PTO 12 JAN 2001

THIS PAGE IS ANK <sup>RECEIVED</sup>

09/743647

100%


WO 00/04157

22 / 23


PCT/GB99/02241

FIG. 14.


A




B




C



D



E



500 Recd PCT/PTO 12 JAN 2001

THIS PAGE BLANK (USPTO)

09/743647


1900 WO 04157

PCT/GB99/02241


23 / 23 -

FIG. 15.


A




B




C



D



E



500 Rec'd PCT/PTO 12 JAN 2001

THIS PAGE BLANK (USPTO)